NZ615720B2 - 3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) - Google Patents

Abstract

Disclosed are 3,4-dihydro-pyrrolo[1,2-a]pyrazin-1-ylamine derivatives of formula I where the substituents are as defined herein. These compounds are inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. Also disclosed are pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid. sitions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.

Description

,4-DIHYDRO-PYRROLO[1,2-a]PYRAZINYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) FIELD OF THE INVENTION The present invention relates to novel 3,4-dihydro-pyrrolo[l,2-a]pyrazin- l-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACEl, Asp2, or memapsin2. The invention is also directed to ceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.

OUND OF THE INVENTION Alzheimer's e (AD) is a neurodegenerative disease associated with aging.

AD patients suffer from cognition deficits and memory loss as well as behavioral problems such as anXiety. Over 90% of those afflicted with AD have a sporadic form of the disorder while less than 10% of the cases are familial or hereditary. In the United States, about 1 in people at age 65 have AD while at age 85, 1 out of every two individuals are affected with AD. The average life ancy from the initial diagnosis is 7-10 years, and AD patients require extensive care either in an assisted living facility which is very costly or by family members. With the increasing number of elderly in the population, AD is a growing medical concern. Currently available therapies for AD merely treat the symptoms of the disease and include acetylcholinesterase inhibitors to e ive properties as well as anXiolytics and ychotics to l the behavioral problems associated with this ailment.

The hallmark pathological features in the brain of AD patients are neurofibrillary 3O s which are generated by hosphorylation of tau protein and d plaques which form by aggregation of beta-amyloid 1-42 (Abeta 1-42) peptide. Abeta 1-42 forms oligomers and then fibrils, and ultimately amyloid plaques. The oligomers and fibrils are believed to be ally neurotoXic and may cause most of the neurological damage associated with AD. Agents that prevent the formation of Abeta 1-42 have the ial to be e-modifying agents for the treatment of AD. Abeta 1-42 is generated from the amyloid precursor protein (APP), sed of 770 amino acids. The N-terminus of Abeta 1-42 is cleaved by beta-secretase (BACE), and then gamma-secretase cleaves the C-terminal end. In addition to Abeta 1-42, gamma-secretase also tes Abeta 1-40 which is the predominant ge product as well as Abeta 1-38 and Abeta 1-43. These Abeta forms can also aggregate to form oligomers and fibrils. Thus, inhibitors ofBACE would be expected to t the formation of Abeta 1-42 as well as Abeta 1-40, Abeta 1-38 and Abeta 1-43 and would be potential therapeutic agents in the treatment of AD.

SUMMARY OF THE INVENTION The present invention is directed to a compound of Formula (I) R2 R3 R1 \ N HN \N RX4 L 2 \ \Ar X1\ 4X3 X2 or a tautomer or a stereoisomeric form thereof, wherein R1, R2, R3 are independently selected from the group consisting of hydrogen, halo, cyano, C1_3alkyl, mono- and polyhalo-C1_3alkyl, and C3_6cycloalkyl; R4 is ed from the group consisting of hydrogen, C1_3alkyl, methoxymethyl, C3_6cycloalkyl, mono- and polyhalo-C1_3alkyl, homoaryl, and heteroaryl; X1, X2, X3, X4 are independently C(RS) or N, provided that no more than two thereof ent N; R5 is selected from the group consisting of hydrogen, halo, cyano, kyl, mono- and lo-C1_3alkyl, and C3_6cycloalkyl; L is a bond or -NHCO-; Ar is homoaryl or heteroaryl; wherein homoaryl is phenyl or phenyl substituted with one, two or three substituents selected from the group consisting of halo, cyano, C1_3alkyl, C1_3alkyloxy, mono- and polyhalo-C1_3alkyl, and mono- and polyhalo-C1_3alkyloxy, heteroaryl is selected from the group consisting of pyridyl, pyrimidyl, pyrazinyl, pyridazyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, thiadiazolyl, oxazolyl, and oxadiazolyl, each ally tuted with one, two or three substituents selected from the group consisting of halo, cyano, kyl, C1_3alkyloxy, mono- and polyhalo- C1_3alkyl, and mono- and polyhalo-C1_3alkyloxy, or an addition salt or a solvate thereof Illustrative of the invention is a pharmaceutical composition comprising a pharmaceutically able r and any of the compounds described above. An illustration of the invention is a pharmaceutical composition made by mixing any of the compounds described above and a pharmaceutically acceptable carrier. Illustrating the invention is a process for making a pharmaceutical composition comprising mixing any of the compounds described above and a pharmaceutically acceptable carrier.

Exemplifying the invention are methods of treating a disorder mediated by the beta-secretase enzyme, comprising stering to a subject in need thereof a therapeutically effective amount of any of the compounds or pharmaceutical itions described above.

Further exemplifying the invention are methods of inhibiting the beta-secretase enzyme, comprising administering to a subject in need thereof a eutically effective amount of any of the compounds or pharmaceutical compositions described above.

An example of the invention is a method of treating a disorder selected from the group consisting of Alzheimer's disease, mild ive impairment, senility, dementia, ia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease and dementia associated with beta-amyloid, preferably Alzheimer's disease, sing administering to a subject in need f a therapeutically effective amount of any of the compounds or pharmaceutical compositions bed above.

Another example of the invention is any of the nds described above for use in treating: (a) Alzheimer's Disease, (b) mild cognitive impairment, (c) senility, (d) dementia, (e) ia with Lewy bodies, (f) Down's syndrome, (g) dementia associated with stroke, (h) dementia associated with Parkinson's disease and (i) dementia associated with beta-amyloid, in a subject in need thereof 3O DETAILED DESCRIPTION OF THE INVENTION The present invention is directed to nds of Formula (I) as defined hereinbefore and pharmaceutically acceptable salts and solvates thereof The compounds of Formula (I) are inhibitors of the ecretase enzyme (also known as beta-site cleaving , BACE, BACEl, Asp2 or memapsin 2), and are useful in the treatment of Alzheimer's e, mild cognitive impairment, senility, dementia, dementia associated with stroke, dementia with Lewy bodies, Down's syndrome, dementia associated with WO 20023 Parkinson's disease and dementia associated with beta-amyloid, preferably Alzheimer's disease, mild cognitive impairment or dementia, more ably Alzheimer's disease.

In an embodiment of the invention, R1, R2, R3 are independently selected from the group consisting of hydrogen, halo, cyano, C1_3alkyl, mono- and polyhalo-C1_3alkyl, and C3_6cycloalkyl, R4 is selected from the group consisting of hydrogen, C1_3alkyl, C3_6cycloalkyl, mono- and polyhalo-C1_3alkyl, homoaryl, and heteroaryl; X1, X2, X3, X4 are independently C(RS) or N, provided that no more than two thereof represent N; R5 is selected from the group consisting of hydrogen, halo, cyano, kyl, mono- and polyhalo-C1_3alkyl, and C3_6cycloalkyl; L is a bond or -NHCO-; Ar is homoaryl or heteroaryl; n homoaryl is phenyl or phenyl substituted with one, two or three substituents selected from the group consisting of halo, cyano, C1_3alkyl, C1_3alkyloxy, mono- and polyhalo-C1_3alkyl, and mono- and polyhalo-C1_3alkyloxy, heteroaryl is selected from the group consisting of pyridyl, pyrimidyl, pyrazinyl, zyl, furanyl, thienyl, pyrrolyl, pyrazolyl, olyl, lyl, thiazolyl, thiadiazolyl, oxazolyl, and oxadiazolyl, each ally substituted with one, two or three substituents selected from the group consisting of halo, cyano, C1_3alkyl, C1_3alkyloxy, mono- and lo-C1_ 3alkyl, and mono- and polyhalo-C1_3alkyloxy, or an addition salt or a solvate thereof In an embodiment of the present invention, R1, R2 and R3 are independently selected from hydrogen and kyl, 3O X1, X2, X3, X4 are independently C(RS) wherein each R5 is selected from hydrogen and halo; L is a bond or —NHCO-; Ar is homoaryl or heteroaryl; wherein homoaryl is phenyl or phenyl substituted with one or two substituents selected from the group consisting of halo, cyano, C1_3alkyl, C1_3alkyloxy, and polyhalo- C1_3alkyloxy, aryl is ed from the group consisting of pyridyl, pyrimidyl, and pyrazinyl, each optionally substituted with one or two substituents ed from the group consisting of halo, cyano, C1_3alkyl, C1_3alkyloxy, and polyhalo-C1_3alkyloxy, or an addition salt or a solvate thereof.

In another embodiment of the present invention, R1, R2 and R3 are hydrogen; X1 is CF; X2, X3, X4 are CH; L is a bond or -NHCO-;Ar is homoaryl or heteroaryl; wherein homoaryl is phenyl substituted with chloro; heteroaryl is selected from the group consisting of pyridyl and pyrimidyl, each ally substituted with one or two tuents selected from the group consisting of chloro, fluoro, cyano, methyl, and methoxy, or an addition salt or a solvate thereof.

In another embodiment, the carbon atom substituted with R4 has the R-configuration.

In an embodiment of the invention, R1 and R3 are hydrogen, 2O R2, is hydrogen, fluoro, or trifluoromethyl; R4 is methyl or difluoromethyl; X1 is CH or CF; X2, X3, and X4 are CH; L is -NHCO-; Ar is ropyridinyl, 5-cyanopyridinyl, 5-fluoropyridinyl, 5-cyano fluorooropyridinyl, 5-methoxypyrazinyl or l-difluoromethylpyrazolyl; or an addition salt or a solvate thereof.

DEFINITIONS 3O "Halo" shall denote fluoro, chloro and bromo; lkyl" shall denote a straight or branched saturated alkyl group having 1, 2 or 3 carbon atoms, e. g. methyl, ethyl, 1-propyl and 2-propyl, "C1_3alkyloxy" shall denote an ether radical wherein C1_3alkyl is as defined before; "mono- and polyhaloC1_3alkyl" shall denote C1_3alkyl as defined before, substituted with l, 2 3 or where possible with more halo atoms as defined before; "mono- and loC1_3alkyloxy" shall denote an ether radical wherein mono- and polyhaloC1_3alkyl is as defined before; "C3_6cycloalkyl" shall denote cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; "C3_6cycloalkanediyl" shall denote a bivalent radical such as cyclopropanediyl, cyclobutanediyl, cyclopentanediyl and cyclohexanediyl.

The term "subj ect" as used herein, refers to an , preferably a mammal, most preferably a human, who is or has been the object of treatment, observation or eXperiment.

The term "therapeutically effective amount" as used , means that amount of active nd or ceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes ation of the symptoms of the disease or disorder being treated.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

Hereinbefore and hereinafter, the term "compound of formula (1)" is meant to include the addition salts, the solvates and the stereoisomers thereof The terms "stereoisomers" or "stereochemically isomeric forms" hereinbefore or hereinafter are used interchangeably.

The nds of a (I) coeXist in a dynamic equilibrium with the compounds of Formula (I-l). fig R1 \ N 4 4 R -:— R X \XZI’ X \Xz’ (I) (H) The invention includes all isomers of the compound of Formula (I) either as a pure stereoisomer or as a mixture of two or more stereoisomers.

Enantiomers are stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemate or racemic e. Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers, i.e. they are not related as mirror images. If a compound contains a double bond, the substituents may be in the E or the Z configuration. If a compound contains a disubstituted lkyl group, the substituents may be in the cis or trans configuration. Therefore, the invention includes enantiomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans s and es thereof The te ration is specified according to the Cahn-Ingold-Prelog system. The configuration at an asymmetric atom is specified by either R or S. Resolved nds whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.

When a specific stereoisomer is identified, this means that said stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1%, of the other s. Thus, when a compound of formula (I) is for instance specified as (R), this means that the compound is substantially free of the (S) isomer; when a compound of formula (I) is for instance specified as E, this means that the compound is substantially free of the Z isomer; when a compound of formula (I) is for instance specified as cis, this means that the nd is substantially free of the trans isomer.

Furthermore, some of the crystalline forms for the nds of the present invention may eXist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds of the present invention may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.

For use in medicine, the salts of the compounds of this invention refer to Xic "pharmaceutically acceptable salts". Other salts may, however, be useful in the preparation of compounds ing to this invention or of their pharmaceutically acceptable salts.

Suitable pharmaceutically acceptable salts of the compounds include acid addition salts which may, for example, be formed by miXing a solution of the compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts f may include alkali metal salts, e.g., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.

Representative acids which may be used in the preparation of ceutically acceptable salts include, but are not limited to, the following: acetic acid, chloroacetic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4- acetamidobenzoic acid, (+)-camphoric acid, rsulfonic acid, capric acid, caproic acid, caprylic acid, ic acid, citric acid, cyclamic acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2012/053863 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucoronic acid, L-glutamic acid, beta-oxo-glutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, (+)-L-lactic acid, (::)-DL-lactic acid, lactobionic acid, maleic acid, (-)-L-malic acid, malonic acid, (::)-DL- mandelic acid, methanesulfonic acid, naphthalenesulfonic acid, naphthalene-1,5- onic acid, l-hydroxynaphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, L- pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, c acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, enesulfonic acid, trifluoromethyl- ic acid, and undecylenic acid. Representative bases which may be used in the preparation of pharmaceutically acceptable salts include, but are not limited to, the following: ammonia, L-arginine, benethamine, benzathine, calcium hydroxide, choline, dimethylethanolamine, diethanolamine, diethylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylene-diamine, N—methyl-glucamine, hydrabamine, lH-imidazole, L-lysine, magnesium hydroxide, 4-(2-hydroxyethyl)-morpholine, piperazine, potassium hydroxide, l-(2-hydroxyethyl)-pyrrolidine, secondary amine, sodium hydroxide, triethanolamine, hamine and zinc hydroxide.

The chemical names of the compounds of the present ion were generated according to the nomenclature rules agreed upon by the Chemical Abstracts Service.

A. Preparation of the final compounds Experimental procedure 1 The final compounds according to Formula (I), can be prepared by reacting an intermediate compound of Formula (II) with an appropriate source of ammonia such as, for example, ammonium chloride or aqueous ammonia, ing to Reaction Scheme (1), a reaction that is med in a suitable on-inert solvent, such as, for example, water or methanol, under thermal conditions such as, for example, heating the on mixture at 60 to 90 °C, for e for 4 to 100 hours. In on Scheme (1), all variables are defined as in Formula (I).

R1 \ N R1 \ N R4 "ammonia source" R4 X4 \ 4 L\ X L\ X X (ll) \XZX (I) \sz Reaction Scheme 1 Experimental procedure 2 Additionally, the final compounds according to a (I-a) n L is , can be prepared by reacting an intermediate compound of Formula (III-a) with an intermediate of Formula (IV) according to Reaction Scheme (2), a reaction that is performed in a suitable reaction-inert solvent, such as, for example, dichloromethane, in the ce of a condensation agent such as for example 4-(4,6-dimethoxy-l,3,5-triazinyl)- 4-methylmorpholinium chloride under thermal conditions such as, for example, heating the reaction mixture at 25 °C, for example for 2 hours. In on Scheme (2), all variables are d as in Formula (I).

R2 R3 R2 R3 \ \ R1 \ N HOT R1 \ N 4 4 R (IV) O R \ 4 \ H HN N X N X N Ar 2 NH2 \\(3 HN2 1| 1| \n/ X\ i’X X\ 22X 0 (Ill-a) x (l-a) x Reaction Scheme 2 Experimental procedure 3 The final compounds according to Formula (I—b) wherein L is a bond, can be prepared by reacting an intermediate compound of Formula (III-b) with an ediate of Formula (V) according to Reaction Scheme (3), a reaction that is performed in a suitable reaction-inert solvent or a mixture of inert ts such as, for example, 1,4-dioxane/ l, in the presence of a suitable base, such as, for example, potassium carbonate, a Pd- complex catalyst such as, for example, tetrakis(triphenyl-phosphine)palladium (0) under 2O thermal conditions such as, for example, heating the reaction mixture at 80 °C, for example for 20 hours or for example, heating the reaction mixture at 150 °C, for 10 min to 30 min under microwave irradiation. In Reaction Scheme (3), all variables are defined as in Formula (I) and W is halo. R6 and R7 may be hydrogen or alkyl, or may be taken together to form for example a bivalent radical of formula —CH2CH2-, -CH2CH2CH2-, or -C(CH3)2C(CH3)2-.

R2 R3 R2 R3 R1 \ N Ar—B\ "R7 R1 \ N H N \N R; W H N \N R; Ar 2 \ 2 \ x1: :g X1: Y3 (Ill-b) x2 (l-b) X2 Reaction Scheme 3 A number of intermediates and starting als in the foregoing ations are known compounds which may be prepared according to art-known methodologies of preparing said or similar compounds and some intermediates are new. A number of such preparation methods will be described hereinafter in more detail.

B. Preparation of the ediate compounds Experimental procedure 4 The intermediates according to Formula ) can be prepared from the corresponding intermediate compounds of Formula (III-b) following own Buchwald- Hartwig type coupling procedures followed by acidic ysis according to Reaction Scheme (4). Said coupling may be conducted by treatment of intermediate compounds of Formula (III-b) with benzophenone imine in a suitable reaction-inert solvent, such as, for example, toluene, in the presence of a suitable base, such as, for example, sodium tert- butoxide, a plex catalyst such as tris(dibenzylideneacetone)dipalladium (0), under thermal conditions such as, for example, heating the reaction mixture at 100 °C, for example for 2 hours. The resulting intermediate nd of Formula (V1) is then transformed into the ediate compound of Formula (III-a) by treatment with a strong 2O acid, such as for e, hydrochloric acid, in a suitable on-inert solvent, such as for example, isopropyl alcohol, under thermal conditions such as, for example, at 25 °C, for example for 1 hour. Alternatively, an intermediate of Formula (III-a) can be obtained in one step starting from an intermediate of Formula (III-b), by mean of a copper-catalyzed coupling in the presence of sodium azide, a ligand for copper, such as N,N ’-dimethyl- ethylenediamine, a suitable base, such as sodium carbonate, in a reaction inert solvent, such as DMSO, under thermal conditions such as heating the reaction e at 110 °C for 25 hours. In Reaction Scheme (4), all variables are defined as in Formula (I) and W is halo. "acid" (Ill-a) Reaction Scheme 4 Experimental procedure 5 The intermediates according to Formula (VII) can be prepared from the corresponding intermediates of Formula (VIII-c) following art-known nitro-to-amino reduction procedures according to Reaction Scheme (5). For example, said reduction may be d out by ng the reactants or passing them through a flow reactor under a hydrogen atmosphere and in the presence of an appropriate catalyst such as, for example, palladium-on-charcoal. Suitable solvents are, for example, water, alkanols, e. g. methanol, ethanol and the like, esters, e. g. ethyl acetate and the like. In order to enhance the rate of said reduction on it may be ageous to elevate the temperature and/or the pressure of the reaction mixture. Undesired further hydrogenation of n functional groups in the reactants and the reaction products may be ted by the on of a catalyst poison such as, for example, thiophene and the like, to the reaction mixture. In Reaction Scheme (5), all variables are defined as in Formula (I).

R2 R3 R2 R3 R1 \ N R1 \ N "nitro to ammo reduction". . .

R4 R4 \s \N X4 N02 \s \N x4 NH2 X\ 23X X\ 22X (VIII-c) X (VII) X Reaction Scheme 5 Experimental procedure 6 The intermediate compounds of Formula (III-a) can be prepared from intermediate compounds of Formula (VII) according to Reaction Scheme (6). Said conversion may conveniently be conducted by treatment of the said intermediate with an a source such as, for example, ammonium de and ethanolic ammonia, under thermal conditions such as, for e, heating the reaction mixture at 80 °C, for example for 72 hours. In Reaction Scheme (6) all variables are defined as in Formula (I). 2 2 R R3 R R3 R1 \ N R1 \ N R4 ' R4 s N HZN N I XYNHZ I XYNHZ (VII) X X (Ill-a) Reaction Scheme 6 Experimental ure 7 An intermediate of a (IX) wherein L is -NHCO-, can be ed by reacting an intermediate compound of Formula (VII) with an intermediate of Formula (IV) according to Reaction Scheme (7), a reaction that is performed in a suitable reaction-inert solvent, such as, for example, methanol, in the presence of a sation agent such as for example, 4-(4,6-dimethoxy-l,3,5-triazinyl)methylmorpholinium chloride, under thermal conditions such as, for example, heating the reaction mixture at 25 °C, for example 2O for 3 hours. In Reaction Scheme (7), all variables are defined as in Formula (I).

R2 R3 R2 R3 R1 \ N HOTAr R1 \ N \ X \ s N NH2 \\(3 3 N x N Ar I I \[1/ x1\ 3 2—,X XK 2—,X o (VII) X (IX) X Reaction Scheme 7 mental procedure 8 The intermediate compounds of Formula (III-b) and (III-c) can generally be prepared following the reaction steps shown in the Reaction Schemes (8) and (9) below.

J§LR31§LR33? NjTjgXrN02 A, (IIIb) X\X (Ill-c) x2 \N \ N 3; :NJG’XSC‘Y3N02 b) X1\X2=X3:;1,§LR3VA RgfiRs‘A B (VIII-c) x1X2'.X3 NEQfl 1;NO (X-b) X (X-c) R2 R3‘XC \ N R1 \ N 3? R4 o N X N02 H | Y X1\ 2—.X3 (XIb) (XI-c) X RECLRG’D D R2 R3 R1 \ N ROZCH2'");ng R020 x4 NO HZN 2 X1\ 21X3 (XIIb) X (XII-C) X R=A|ky| PGHN];R020 R020 PGHN \CNOZ (XIII-b) (XIII-c) A: Thioamide-to-amidine conversion A’: Methyltio to amino conversion B: Methylation of the sulfur C: to-thioamide conversion (thionation) D: Cyclization E: Removing any N—protecting groups The e derivatives in the above Reaction Scheme (8) may be conveniently prepared from the corresponding thioamide derivatives following art-known thioamide-to- amidine conversion ures (reaction step A). Said conversion may conveniently be conducted by treatment of the said thioamides with an ammonia source such as, for example, ammonium de or s ammonia, in a suitable reaction-inert solvent such as, for example, water or methanol and the like, under thermal conditions such as, for example, heating the reaction mixture at 60 to 90 °C, for example for 6 to 100 hours. Under similar conditions, also the methylated intermediates (VIII-b) and (VIII-c) can be converted into the desired amidines (reaction step A’). Intermediates (VIII-b) and (VIII-c) can be conveniently prepared starting from the corresponding thioamides, dissolved in a suitable t, such as acetone, in the presence of a base, such as potassium carbonate, and a methylating agent, such as methyl iodide, under thermal conditions such as room temperature for 3 hours (reaction step B).

The thioamide derivatives in the above Reaction Scheme (8) can be prepared from amide derivatives following art-known thionation procedures (reaction step C). Said conversion may conveniently be conducted by treatment of the said amides with a tion agent such as, for example, phosphorous pentasulfide or 2,4-bis-(4-methoxy- phenyl)-1,3-dithia-2,4-diphosphetane 2,4-disulf1de [Lawesson’s t], in a reaction inert solvent such as, for example, tetrahydrofuran or oxane and the like, in the presence of a suitable base like pyridine under thermal conditions such as, for example, heating the on e at 50 to 100 °C, for example for 24 hours.

The amide derivatives of Formula (XI-b) and (XI-c) in the above on Scheme (8) can be prepared from the corresponding intermediate compounds of Formula (XII-b) and (XII-c) following art-known cyclization procedures (reaction step D). Said cyclization may conveniently be conducted by treatment of intermediate compounds of Formula (XII-b) and (XII-c) with a suitable base, such as potassium acetate or sodium methoxyde, in a le reaction solvent, such as for example ethanol and the like, at 55 °C to 100 °C, for a period of time to ensure the tion of the reaction.

The intermediate compounds of Formula (XII-b) and ) in the above Reaction Scheme (8) can be prepared from the corresponding intermediate compounds of Formula b) and (XII-c) by removal of the protecting group being carried out according to processes known in the art.

Experimental procedure 9 (XIII-b) (XIII-c) O’S‘N(PWX‘l I Y ‘21 X \XZ’, X1 3 (XVI-b) bx" NO2 "l \ 1 1 z X\X2,, (XVII-B) (XVII-c) on Scheme 9 F: Alkylation G: Oxathiazolidine oxidation H: Oxathiazolidine formation The intermediates according to Formula (XIII-b) and (XIII-c) in the above on Scheme (9) can be ed from the corresponding ediate compounds of Formula (XV-b) and (XV-c), wherein Z1 is a protecting group of amines such as, for example, the tert—butoxycarbonyl group, following art-known alkylation procedures (reaction step F).

Said alkylation may conveniently be conducted by treatment of (XV-b) and (XV-c) respectively with the corresponding intermediate compounds of Formula (XIV) in the presence of a suitable base such as, for example, sodium carbonate or cesium carbonate, in a suitable inert solvent such as, for example, N,N—dimethyl formamide or dimethoxysulfoxide, at low ature such as, for example, 0 °C for 30 min and then at a tely high temperature such as, for example, 100 °C for 24 hours to 100 hours or for example, heating the reaction mixture at 130 °C, for e for 30 min to 45 min. under microwave ation.

The intermediates according to a (XV-b) and (XV-c) in the above Reaction Scheme (9) can be ed by reacting the intermediate compounds of Formula (XVI-b) and (XVI-c) following art-known oxidation ures (reaction step G). Said oxidation may conveniently be conducted by ent of the corresponding intermediate compounds of Formula (XVI-b) and (XVI-c) with an oxidant agent such as, for e, sodium periodate in a suitable inert solvent such as, for example, acetonitrile/water, in the presence of ruthenium (III) chloride at a moderately high temperature such as, for example, 25 °C, for example for 2 hours.

The intermediates ing to Formula (XVI-b) and (XVI-c) in the above Reaction Scheme (9) can be prepared by reacting the intermediate compounds of Formula (XVII-b) and (XVII-c) following art-known sulfamidate formation procedures (reaction step H). Said transformation may conveniently be conducted by ent of the 2O corresponding intermediate compounds of Formula (XVII-b) and (XVII-c) with thionyl chloride in the presence of a base such as, for example, pyridine, in a suitable reaction- inert solvent, such as, for example, acetonitrile, at low temperature such as, for e, - 40 °C, for example for 30 min and then at a moderately high temperature such as, for example, 25 °C, for example for 24 to 72 hours.

The intermediates compounds of Formula (XVII-b) and (XVII-c), wherein Z1 is a protecting group of amines such as, for example, the tert—butoxycarbonyl group, can generally be prepared following art-known Strecker type procedures described in literature.

Experimental procedure 10 3O The ediate compounds of Formula (XVIII) wherein Q is halo or nitro, can be prepared from intermediate compounds of Formula (XI-b) or (XI-c) according to Reaction Scheme (14), a on that is performed in a suitable reaction-inert t, such as for example, dichloromethane, in the presence of a ating agent, such as for example, trimethyl-oxonium tetrafluoroborate, under thermal conditions, such as for example, at 25 °C, for example for 4 days. Intermediate (XVIII) can then be further converted into amidines (III-b) and (III-c) by reaction with an a source such as, for example, ammonium chloride and ethanolic ammonia, under thermal conditions such as, for _ 17 _ example, heating the reaction mixture at 80 °C, for example for 36 hours. In Reaction Scheme (10) all variables are defined as in Formula (I) and Q is halo or nitro.

R2 R3 R2 R3 R2 R3 R1 \ N R1 \ N R1 \ N R4 R4 "ammonia source" R4 \ \ 0/ N X4 \o Q N Y X4\\(Q HZN N X4 Q H I X1| I Y (XI-b or c) (xvm) (Ill-b or c) Reaction Scheme 10 PHARMACOLOGY The compounds of the present invention and the pharmaceutically acceptable compositions thereof inhibit BACE and therefore may be useful in the treatment or prevention of Alzheimer’s e (AD), mild cognitive impairment (MCI), senility, dementia, ia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down’s syndrome, dementia associated with Parkinson’s disease and dementia associated with beta-amyloid.

The invention relates to a compound according to the l Formula (I), a stereoisomeric form thereof or a pharmaceutically acceptable acid or base addition salt or a solvate thereof, for use as a medicament.

The invention also relates to a compound according to the l Formula (I), a stereoisomeric form thereof or a the pharmaceutically able acid or base addition salt or a e thereof, for use in the treatment or prevention of diseases or conditions selected from the group consisting of AD, MCI, senility, dementia, ia with Lewy bodies, al d angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with Parkinson's disease and dementia associated with beta-amyloid.

The invention also relates to the use of a compound according to the general Formula (I), a stereoisomeric form thereof or a pharmaceutically acceptable acid or base addition salt or a e thereof, for the manufacture of a medicament for the treatment or prevention of any one of the disease conditions ned hereinbefore.

In view of the utility of the nd of Formula (I), there is provided a method of treating warm-blooded animals, including humans, suffering from or a method of preventing warm-blooded s, including humans, to suffer from any one of the diseases mentioned hereinbefore.

Said methods comprise the administration, i.e. the systemic or l administration, preferably oral administration, of an effective amount of a compound of Formula (I), a stereoisomeric form thereof, a ceutically acceptable addition salt or e thereof, to a warm-blooded animal, including a human.

A method of treatment may also include administering the active ingredient on a regimen of between one and four intakes per day. In these methods of treatment the compounds according to the invention are preferably formulated prior to administration. As described herein below, suitable pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients.

The nds of the present ion, that can be suitable to treat or prevent Alzheimer's disease or the symptoms thereof, may be administered alone or in combination with one or more additional therapeutic agents. Combination therapy includes administration of a single pharmaceutical dosage formulation which ns a nd of Formula (I) and one or more additional therapeutic agents, as well as administration of the compound of Formula (I) and each additional therapeutic agents in its own separate pharmaceutical dosage formulation. For example, a compound of Formula (I) and a therapeutic agent may be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent may be administered in separate oral dosage ations.

PHARMACEUTICAL COMPOSITIONS The t invention also provides compositions for preventing or treating es in which inhibition of beta-secretase is beneficial, such as Alzheimer's disease (AD), mild cognitive impairment, senility, ia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease and dementia associated with beta-amyloid. Said compositions comprising a therapeutically effective amount of a compound according to formula (I) and a pharmaceutically acceptable carrier or diluent.

While it is possible for the active ingredient to be administered alone, it is 3O preferable to present it as a ceutical ition. Accordingly, the present ion further provides a pharmaceutical composition comprising a compound according to the present invention, together with a pharmaceutically acceptable carrier or diluent. The carrier or diluent must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not rious to the ents thereof.

The pharmaceutical compositions of this invention may be prepared by any methods well known in the art of pharmacy. A therapeutically effective amount of the particular compound, in base form or addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of ation desired for administration. These pharmaceutical compositions are desirably in y dosage form suitable, preferably, for systemic administration such as oral, percutaneous or parenteral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. For example, in ing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions: or solid carriers such as starches, , kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, s and capsules represent the most advantageous oral dosage unit form, in which case solid ceutical carriers are sly employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Inj e solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.

Injectable suspensions may also be prepared in which case appropriate liquid carriers, ding agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which ves do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a n or as an ointment.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and mity of dosage.

Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active 3O ingredient calculated to e the d therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, inj ectable ons or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof The exact dosage and frequency of administration depends on the particular compound of Formula (I) used, the ular condition being treated, the severity of the ion being treated, the age, , sex, extent of disorder and general al condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. rmore, it is evident that said effective daily amount may be d or increased ing on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention.

Depending on the mode of administration, the pharmaceutical composition will comprise from 0.05 to 99% by weight, preferably from 0.1 to 70% by weight, more preferably from 0.1 to 50% by weight of the active ingredient, and, from 1 to 99.95% by weight, preferably from 30 to 99.9% by weight, more preferably from 50 to 99.9% by weight of a pharmaceutically acceptable carrier, all percentages being based on the total weight of the composition.

The present compounds can be used for systemic stration such as oral, percutaneous or eral administration; or topical administration such as via inhalation, a nose spray, eye drops or via a cream, gel, shampoo or the like. The compounds are preferably orally administered. The exact dosage and frequency of administration depends on the particular compound according to Formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight, sex, extent of disorder and l physical ion of the particular t as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is t that said effective daily amount may be lowered or increased depending on the 2O response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant ion.

The amount of a nd of Formula (I) that can be combined with a carrier material to produce a single dosage form will vary depending upon the disease treated, the mammalian species, and the particular mode of administration. However, as a general guide, suitable unit doses for the compounds of the present invention can, for example, preferably contain between 0.1 mg to about 1000 mg of the active compound. A preferred unit dose is between 1 mg to about 500 mg. A more preferred unit dose is n 1 mg to about 300mg. Even more preferred unit dose is between 1 mg to about 100 mg. Such unit doses can be administered more than once a day, for e, 2, 3, 4, 5 or 6 times a day, 3O but preferably 1 or 2 times per day, so that the total dosage for a 70 kg adult is in the range of 0.001 to about 15 mg per kg weight of subject per administration. A preferred dosage is 0.01 to about 1.5 mg per kg weight of subject per administration, and such therapy can extend for a number of weeks or months, and in some cases, years. It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of ion; other drugs that have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those of skill in the area.

It can be necessary to use dosages outside these ranges in some cases as will be nt to those skilled in the art. Further, it is noted that the clinician or treating physician will know how and when to start, interrupt, adjust, or terminate therapy in conjunction with indiVidual patient response.

The following examples are intended to illustrate but not to limit the scope of the present invention.

Experimental Part Hereinafter, the term "AcOH" means acetic acid, "AcOEt" means ethyl e, "DCM" means dichloromethane, "DIPE" means diisopropylether, "DMF" means N,N—dimethylformamide, "DMSO" means dimethylsulfoXide, "EtzO" means diethylether, "Et3N" means triethylamine, "EtOH" means ethanol, "MeCN" means acetonitrile, "DCE" means 1,2-dichloroethane, "MeOH" means methanol, "mp." means melting point, "rac" means racemic, "Rt" means retention time, "THF" means tetrahydrofuran, "K2C03" means potassium carbonate, "NH3" means ammonia, "NH4Cl" means ammonium chloride, "HCl" means hydrochloric acid, "NaZSO4" means sodium sulphate, "NaHC03" means sodium bicarbonate, "KHSO4" means potassium hydrogenosulphate, "MgSO4" means magnesium sulphate, "H20" means water, "TFA" means trifluoroacetic acid, "sat." means saturated, "aq." means aqueous, "min" means min, ba)3" means tris(dibenzylideneacetone)dipalladium (0), "Pd(PPh3)4" means tetrakis(triphenylphospine)palladium (0) " means 2,2'-bis(diphenylphosphino)- 1,l'-binaphthyl, "TBAF" means tetrabutylammonium fluoride, "NaH" means sodium e, "DDQ" means 2,3-dichloro-5,6-dicyano-l,4-benzoquinone, "DBU" means 1,8- diazabicyclo[5.4.0]undecene.

Microwave assisted reactions were performed in a single-mode reactor: EmrysTM Optimizer ave reactor (Personal Chemistry A.B., currently Biotage).

Hydrogenation reactions were performed in a uous flow hydrogenator 3O H-CUBE® from ThalesNano chnology Inc.

Thin layer chromatography (TLC) was d out on silica gel 60 F254 plates (Merck) using reagent grade solvents. Open column chromatography was performed on silica gel, particle size 60 A, mesh = 23 0-400 (Merck) under standard techniques. Flash column chromatography was performed using ready-to-connect cartridges from Merck, on irregular silica gel, particle size 15-40 mm (normal layer disposable flash columns) on a SPOT or H system from Armen Instrument.

WO 20023 Optical ons were measured on a Perkin-Elmer 341 polarimeter with a sodium lamp and reported as follows: [oc]° (7», c l, solvent, T°C).

A. Preparation of the intermediates Example Al Preparation of intermediate Al: Trimethylsilylcyanide (20 g, 200 mmol) was added to a stirred on of 3-bromoacetophenone (20 g, 100 mmol) and NH4Cl (11 g, 200 mmol) in NH3/MBOH (400 mL).

The mixture was stirred at room temperature for 4 days. Then the solvent was evaporated in vacuo and the residue was taken up in AcOEt (100 mL). The solid was filtered off and the te was evaporated in vacuo to yield intermediate A1 (20 g, 86% yield), which was used in the next step without further purification.

Example A2 Preparation of intermediate A2: 0\ / H2N 0 Intermediate A1 (20 g, 88.9 mmol) was dissolved in OH (500 mL). The mixture was refluxed for 4 days. After cooling to room temperature, AcOEt (100 mL) and H20 (100 mL) were added and the mixture was extracted with AcOEt (2 x 100 mL). The combined aq. layers were basified with an aq. solution of NH3 to pH = 8 2O and extracted with AcOEt (5 x 100 mL). The combined organic layers were dried (Na2S04), filtered and the solvents evaporated in vacuo to yield intermediate A2 (10.6 g, 46% yield) as an oil.

The following intermediate was prepared according to the synthetic procedures described in examples Al-A2: Example A3 Preparation of intermediate A3: _ 23 _ From racamino(3 -nitro-phenyl)-propionitrile. Flash column chromatography (silica gel; AcOEt in petroleum ether 1/10 to 1/4) to yield ediate 3 (63% yield).

Example A4 Preparation of intermediate A4: Lithium aluminium hydride (1 M in THF; 22 mL, 22 mmol) was added dropwise to a stirred on of intermediate A2 (7.5 g, 29.1 mmol) in THF (200 mL) at -15 °C. The mixture was left warming up slowly to 0 °C during 1 hour. More THF (150 mL) was added and a sat. solution of. NaZSO4 was added dropwise until no more hydrogen was . ous NaZSO4 was added and the reaction allowed to stir overnight at room temperature. The mixture was filtered over diatomaceous earth, washed with THF and the solvent evaporated in vacuo. The crude product was purified by flash column chromatography (silica gel; 7 M solution of NH3 in MeOH in DCM 0/100 to 3/97). The desired fractions were collected and the solvents evaporated in vacuo to yield ediate A4 (5.70 g, 85% yield) as an oil.

Example A5 Preparation of intermediate A5: 9- H2N Sodium borohydride (16.3 g, 429.4 mmol) was added portionwise to a stirred solution of intermediate A3 (48.3 g, 214.7 mmol) in MeOH (500 mL). The mixture was stirred at room temperature for 10 hours. The solvent was evaporated in vacuo. The residue was basified with a sat. aq. solution of NaHC03 until pH = 9 and extracted with AcOEt (3 x 200 mL). The c layers were dried 4), filtered and the solvents evaporated in vacuo to yield intermediate A5 (30.26 g, 72% yield). 2012/053863 Example A6 Preparation of intermediate A6: HN/Z< HO C Benzoyl chloride (4.66 mL, 32.6 mmol) was added portionwise to a stirred solution of intermediate A4 (5 g, 21.73 mmol) in a mixture of sat. NaHC03 (10 mL) and THE (10 mL) at 0 °C. The mixture was stirred at 0 °C for 10 min and at room temperature for 15 hours. The mixture was cooled in an ice/HzO bath and acidified with ng to pH = 1-2 with KHSO4. The organic layer was separated and the aq. layer was further extracted with AcOEt. The combined organic layers were separated, dried (MgSO4), filtered and the solvents ated in vacuo. The crude product was purified by flash column chromatography (silica gel; AcOEt in DCM 0/100 to 20/80). The desired fractions were collected and trated in vacuo to yield ediate A6 (7.8 g, 98% yield) as a less oil.

Example A7 Preparation of intermediate A7: OS\ Br C?O/kO A solution of intermediate A6 (8 g, 21.9 mmol) in dry MeCN (20 mL) was added dropwise to a stirred solution of thionyl chloride (4.01 mL, 54.9 mmol) in dry MeCN (100 mL) cooled to -40 °C and under a nitrogen atmosphere. The reaction mixture was stirred for 60 min at -40 °C before pyridine (8.84 mL, 109.8 mmol) was added. The reaction was 2O allowed to warm to room temperature and stirred for 14 hours. The solvent was evaporated in vacuo. The residue was treated with EtZO and the solids were filtered off and the filtrate concentrated in vacuo to yield intermediate A7 (8 g, 89% yield) as a pale yellow oil. The product was used in the next reaction without further purification.

Example A8 ation of intermediate A8: Ruthenium (III) de (41 mg, 0.195 mmol) was added to a mixture of intermediate A7 (8 g, 19.5 mmol) in MeCN/ H20 (1:1) (210 mL) at 0 °C, followed by the addition of sodium periodate (6.26 g, 29.25 mmol). The reaction was allowed to warm to room temperature and stirred for 2 hours. The mixture was diluted with AcOEt, filtered through diatomaceous earth and washed with AcOEt. H20 and AcOEt were added to the filtrate.

The organic layer was separated, dried (MgSO4), filtered and the solvents evaporated in vacuo. The product was purified by flash column tography (silica gel; DCM). The d fractions were ted and concentrated in vacuo to yield intermediate A8 (8 g, 96% yield) as a pale yellow oil.

Example A9 Preparation of intermediate A9: -QN+ HNJ Example A10 Preparation of intermediate A10: _ 26 _ <9 9- 9st N: O k 0 O O A solution of intermediate A9 (4.5 g, 15.18 mmol) in dry MeCN (20 mL) was added dropwise to a stirred solution of l chloride (2.771 mL, 37.96 mmol) in dry MeCN (80 mL) cooled to -40 °C and under a nitrogen atmosphere. The reaction e was stirred for 30 min at -40 °C before pyridine (6.12 mL, 75.93 mmol) was added. The reaction was allowed to warm to room temperature and stirred for 18 hours. The solvent was evaporated in vacuo. The residue was treated with EtZO. The solids were filtered off and the filtrate concentrated in vacuo to yield intermediate A10 (4.8 g, 92% yield) as an oil. The product was used in the next reaction without further purification.

Example A11 Preparation of intermediate A11 Q‘s/O \\ I Ruthenium (III) chloride (29.5 mg, 0.14 mmol) was added to a e of intermediate A10 (4.8 g, 14.02 mmol) in MeCN/ H20 (1:1) (100 mL) at 0 °C, followed by the addition of sodium periodate (4.5 g, 21.03 mmol). The reaction was d to warm to room temperature and stirred for 2 hours. The e was diluted with AcOEt, filtered through diatomaceous earth and washed with AcOEt. H20 and brine were added to the te. The organic layer was separated, dried (MgSO4), filtered and the ts evaporated in vacuo.

The product was purified by flash column chromatography (silica gel; DCM). The desired fractions were collected and concentrated in vacuo to yield intermediate All (4.9 g, 97% 2O yield) as a pale yellow oil.

The intermediate A12 was ed according to the synthetic procedures described in examples A9-A11: Example A12 Preparation of intermediate A12: (R)-[3-(tert—butyloxycarbonyl)(5-bromo fluorophenyl)methyl-[1,1,3]oxathiazolidine-2,2-dioxide W0 20023 o\\/ o" ‘N to Br Prepared from (R)-[3-(tert—butyloxycarbonyl)(5-bromofluorophenyl)methyl- [1,1,3]oxathiazolidineoxide (14.5 g, 36.79 mmol). Flash column chromatography (silica gel; DCM) to yield intermediate A12 as a white solid (11.6 g, 77% yield).

Example A13 Preparation of ingermediate A13: 53%;? Cesium carbonate (3.06 g, 9.83 mmol) was added to a e of ediate A8 (2 g, 4.69 mmol) and 1H-pyrrolecarboxylic acid ethyl ester (763 mg, 6.1 mmol) in MeCN (16 mL) at room temperature. The mixture was heated at 130 °C for 30 min under microwave irradiation. The mixture was diluted with DCM and washed with H20. The organic phase was separated and treated with H20 (10 mL) and extracted with DCM (2 x 10 mL). The c layer was separated, dried (Na2S04), filtered and the solvents evaporated in vacuo. The crude product was purified by flash column chromatography (silica gel; DCM). The desired fractions were ted and the solvents evaporated in vacuo to yield intermediate A13 (1.7 g, 77% yield) as a colorless oil.

Example A14 Preparation of intermediate A14: 1 \ Br V0 N Boron trifluoride-diethyl etherate (4.53 mL, 36.1 mmol) was added to intermediate A13 (1.7 g, 3.61 mmol) followed by ethanethiol (8.01 mL, 108.2 mmol) at 0 °C in a sealed tube.

The mixture was allowed to warm to room temperature and was stirred at 60 °C for 3 hours. The solvents were evaporated in vacuo and the residue was dissolved in DCM and washed with sat. NaHC03. The organic layer was separated, dried (Na2S04), filtered and the ts evaporated in vacuo. The crude product was purified by flash column chromatography (silica gel, AcOEt in DCM, 0/100 to 50/50). The desired fractions were collected and the solvents ated in vacuo to yield intermediate A14 (950 mg, 78% yield) as a colorless oil.

Example A15 Preparation of intermediate A15: gr"N O HE» Sodium methoxyde 25 wt. % in MeOH (1.284 mL, 5.36 mmol) was added to a solution of ediate A14 (950 mg, 2.82 mmol) in MeOH (8 mL) at room temperature. The mixture was stirred at 55 °C for 18 hours. The solvent was evaporated in vacuo. The residue was d with an aq. sat. solution of NH4Cl and extracted with DCM. The organic layer was separated, dried (Na2S04), filtered and the solvents evaporated in vacuo to yield intermediate A15 (850 mg, 99% yield) as a white solid used in the following step t further purification.

Example A16 Preparation of intermediate A16: Phosphoruspentasulfide (940 mg, 4.23 mmol) was added to a solution of intermediate A15 (860 mg, 2.82 mmol) in pyridine (7 mL) and the mixture was heated at 110 °C for 38 hours.

The t was evaporated in vacuo and the crude product was purified by short column chromatography (silica gel, AcOEt in DCM 0/100 to . The desired fractions were collected and the solvents evaporated in vacuo to yield intermediate A16 (830 mg, 92% yield) as a yellow solid.

Example A17 Preparation of intermediate A17: W0 2012/120023 Methyl iodide (0.267 mL, 4.296 mmol) and K2C03 (0.59 g, 4.296 mmol) were added to a solution of intermediate A16 (690 mg, 2.15 mmol) in acetone (10 mL) and the mixture was stirred at room temperature for 3 hours. The solvent was evaporated in vacuo and the crude product taken up in DCM (25 mL) and H20 (25 mL). The organic layer was separated, dried (MgSO4), filtered and the ts evaporated in vacuo. The crude product was purified by flash column chromatography (silica gel; AcOEt in DCM, 0/100 to 50/50).

The desired fractions were collected and the solvents evaporated in vacuo to yield intermediate A17 (700 mg, 97% yield) as a pale yellow solid. e A18 Preparation of intermediate A18: _ KgBr NH4Cl (447 mg, 8.35 mmol) was added to a suspension of intermediate A17 (700 mg, 2.09 mmol) in a 2 M solution of NH3 in EtOH (39.67 mL, 7934 mmol) and the mixture was heated at 90 °C for 24 hours. The solvent was evaporated in vacuo and the residue suspended in a 2 M on of NH3 in EtOH (20 mL, 40 mmol). NH4Cl (447 mg, 8.35 mmol) was added and the mixture was heated at 90 °C for 2 days. The t was evaporated in vacuo and the residue suspended on DCM and washed with H20. The organic layer was separated, dried (MgSO4), filtered and the solvents evaporated in vacuo.

The product was purified by flash column chromatography (silica gel; 7 M solution ofNH3 in MeOH/DCM 0/100 to 20/80). The desired ons were collected and the solvents evaporated in vacuo to yield intermediate A18 (550 mg, 86% yield) as a pale yellow solid.

Example A19 Preparation of intermediate A19: O N 4L0 @N‘O\\ l // NH 0- WO 20023 Cesium carbonate (2.73 g, 8.37 mmol) was added to a mixture of intermediate All (1.5 g, 4.186 mmol) and 1H-pyrrolecarboxylic acid ethyl ester (681 mg, 5.441 mmol) in MeCN (16 mL). The mixture was stirred at 130 °C for 30 min under microwave irradiation. The reaction mixture was diluted with DCM and washed with aq. HCl (1 N). The organic layer was separated, dried 4), filtered and the solvents evaporated in vacuo. The crude product was purified by flash column chromatography (silica gel; DCM). The desired fractions were ted and the solvents evaporated in vacuo to yield intermediate A19 (1.5 g, 89% yield) as a colorless oil.

Example A20 Preparation of ediate A20: 0 @430N H2N O- HCl (9.295 mL, 37.181 mmol, 4 M in 1,4-dioxane) was added to intermediate A19 (1.5 g, 3.718 mmol) and the mixture was d at room temperature for 1 hour. The solvent was evaporated in vacuo and the residue suspended in DCM and washed with an aq. sat. solution of NaHC03. The organic layer was separated, dried (Na2S04), filtered and the solvents evaporated in vacuo to yield intermediate A20 (1.1 g, 97% yield) used in the next reaction step without further purification.

Example A21 2O Preparation of intermediate A21: O %\/Q Sodium methoxyde 25 wt. % in MeOH (0.909 mL, 3.99 mmol) was added to a on of intermediate A20 (1.1 g, 3.63 mmol) in MeOH (10 mL) at room temperature. The mixture was stirred at 65 °C for 18 hours. The solvent was evaporated in vacuo. The residue was treated with an aq. sat. solution of NH4Cl and extracted with DCM. The c layer was separated, dried (Na2S04), filtered and the solvents evaporated in vacuo. The crude product was purified by flash column tography (silica gel; AcOEt). The desired fractions were collected, the solvents evaporated in vacuo and the resulting residue was triturated with DIPE to yield intermediate A21 (650 g, 66% yield) as a white solid.

Example A22 Preparation of ediate A22: S %\l/O Phosphoruspentasulfide (799 mg, 3.59 mmol) was added to a solution of intermediate A21 (650 mg, 2.4 mmol) in pyridine (10 mL) and the mixture was heated at 100 °C for 18 hours.

The solvent was evaporated in vacuo and the crude product was purified by short column chromatography a gel, AcOEt in DCM 0/100 to 100/0). The desired fractions were collected and the solvents evaporated in vacuo to yield intermediate A22 (535 mg, 78% yield) as a yellow solid.

Example A23 Preparation of intermediate A23: \S \N "0 Methyl iodide (0.232 mL, 3.724 mmol) and K2C03 (0.515 g, 3.724 mmol) were added to a solution of intermediate A22 (535 mg, 1.86 mmol) in acetone (10 mL) and the mixture was stirred at room temperature for 3 hours. The solvent was evaporated in vacuo and the crude t taken up in DCM (25 mL) and H20 (25 mL). The organic layer was separated, and the aq. layer was extracted with DCM (3 x 25 mL). The combined c layers were dried (MgSO4), filtered and the solvents evaporated in vacuo. The crude product was d by flash column tography (silica gel, AcOEt in DCM, 0/100 to 50/50). The desired fractions were collected and the solvents evaporated in vacuo to yield intermediate A23 (490 mg, 87% yield) as a pale yellow solid. e A24 Preparation of intermediate A24: §N \S \N A solution of intermediate A23 (490 mg, 1.626 mmol) in EtOH (28 mL) was hydrogenated in a H-cube reactor (1 mL/min, 30 mm Pd/C 5% cartridge, full H2 mode, room temperature, 2 cycles). Then, the solvents evaporated in vacuo. The crude product was purified by flash column chromatography a gel; 7 M NH3 in MeOH in DCM, 0/100 to 10/90). The desired fractions were collected and the solvents evaporated in vacuo to yield intermediate A24 (100 mg, 23% yield) as a colorless oil.

Example A25 Preparation of intermediate A25: _ NH2 NH4Cl (78.8 mg, 1.474 mmol) was added to a solution of intermediate A24 (100 mg, 0.368 mmol) in a 2 M solution of NH3 in EtOH (7 mL, 14 mmol) and the mixture was heated at 80 °C for 3 days. The solvent was ated in vacuo and the residue suspended in DCM and washed with H20. The organic layer was separated, dried (MgSO4), d and the solvents evaporated in vacuo. The product was purified by flash column chromatography (silica gel; 7 M solution of NH3 in MeOH/DCM 0/100 to 20/80). The desired ons were collected and the solvents evaporated in vacuo to yield intermediate A25 (80 mg, 90% yield) as a pale yellow solid.

Example A26 Preparation of intermediate A26: \ / CI 0 N -Chloro-pyridinecarboxylic acid (172 mg, 1.09 mmol) was added to a solution of 4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (330 mg, W0 20023 1.19 mmol) in MeOH (5 mL). The mixture was stirred at room ature for min. Then the mixture was cooled to 0 °C and a on of intermediate A24 (270 mg, 0.995 mmol) in MeOH (5 mL) was added. The mixture was warmed to room temperature and stirred for 3 hours. The mixture was treated with a sat. solution of Na2C03 and H20 and extracted with DCM. The organic layer was separated, dried (MgSO4), filtered and the solvents evaporated in vacuo. The crude product was purified by flash column chromatography (silica gel; AcOEt in heptane 50/50). The desired fractions were collected and the solvents evaporated in vacuo to yield intermediate A26 (200 mg, 49% yield) as a white solid.

Example A27 Preparation of intermediate A27: Br F O o GAO/k Cesium carbonate (18.27 g, 56.06 mmol) was added to a mixture of intermediate A12 (11.5 g, 28.01 mmol) and 1H-pyrrolecarboxylic acid ethyl ester (4.56 g, 36.44 mmol) in MeCN (40 mL) at room temperature. The e was d at room temperature for 20 min and then it was heated at 130 °C for 30 min under microwave irradiation. The mixture was diluted with DCM and washed with H20. The organic phase was dried (Na2S04), d and the solvents evaporated in vacuo. The crude product was purified by flash column chromatography (silica gel; DCM/heptane, 90/10). The desired 2O fractions were collected and the solvents evaporated in vacuo to yield intermediate A27 (10.7 g, 83% yield) as a sticky solid.

Example A28 Preparation of intermediate A28: V0 N 0 R HCl (15 mL, 60 mmol, 4M in 1,4-dioxane) was added to ediate A27 (9.5 g, 20.864 mmol) and the mixture was stirred at room temperature for 90 min. The solvent was evaporated in vacuo to yield intermediate A28 (10 g, impure, 122% yield), used in the next on step without further purification.

Example A29 Preparation of intermediate A29: NR F Sodium methoxide 25 wt. % in MeOH 4 mL, 68.93 mmol) was added to a on of intermediate A28 (950 mg, 2.82 mmol) in MeOH (30 mL) at room temperature. The mixture was stirred at 60 °C for 18 hours. The solvent was evaporated in vacuo. The residue was treated with an aq. sat. solution of NH4Cl and extracted with DCM. The c layer was separated, dried (Na2S04), filtered and the solvents evaporated in vacuo.

The crude product was purified by flash column chromatography (silica gel, AcOEt in DCM 0/100 to . The desired fractions were collected and the solvents ated in vacuo to yield intermediate A29 (1.5 g, 18% yield) as white solid.

Example A30 Preparation of intermediate A30: \R F hyloxonium tetrafluoroborate (2.56 g, 17.33 mmol) was added to a solution of intermediate A29 (1.4g, 4.33 mmol) in DCM (5 mL) at room temperature. The mixture was stirred at room temperature for 4 days. The reaction mixture was diluted and then was 2O treated with a cold aq. sat. solution of NaHC03. The organic layer was separated, dried (MgSO4), filtered and the solvents evaporated in vacuo to yield intermediate A30 (910 mg, 62% yield) as an off-white solid used in the next reaction step without further purification.

Example A31 Preparation of intermediate A31: W0 2012/120023 _ 35 _ —R Br NH4Cl (577 mg, 10.79 mmol) was added to a solution of intermediate A30 (910 mg, 2.7 mmol) in a 2 M solution of NH3 in EtOH (5 mL, 10 mmol) and the mixture was heated at 80 °C for 36 hours into a sealed tube. The mixture was cooled to room temperature and NH4Cl (432 mg, 8.1 mmol) and a 2 M solution of NH3 in EtOH (5 mL, 10 mmol) were added and the mixture was heated at 80 °C for 36 hours into a sealed tube. The mixture was cooled to room temperature and NH4Cl (432 mg, 8.1 mmol) and a 2 M solution of NH3 in EtOH (5 mL, 10 mmol) were added and the mixture was heated at 80 °C for 48 hours into a sealed tube. The solvent was evaporated in vacuo and the residue suspended on DCM and washed with H20 (4-5 mL). The organic layer was separated, dried (MgSO4), filtered and the solvents evaporated in vacuo. The ing crude product was taken up in DCM and the precipitated solid was filtered off to yield ediate A31 (458 mg, 53% yield) as a white solid.

Example A32 Preparation of ediate A32: — R NH2 HZN F Sodium tert—butoxide (0.329 g, 3.43 mmol) was added to a mixture of intermediate A31 (0.41 g, 1.143 mmol) in toluene (8.7 mL). The mixture was stirred for 5 min and then rac- BINAP (0.213 g, 0.343 mmol) and Pd2(dba)3 (105 mg, 0.114 mmol), were added under nitrogen atmosphere at room temperature. The mixture was flushed with nitrogen for a few min and then benzophenone imine (0.383 mL, 2.286 mmol) was added and the mixture was stirred at 100 °C for 2 hours. After cooling to room temperature, the e was diluted with H20 and extracted with DCM. The organic layer was separated, dried ), filtered and the solvents ated in vacuo. The crude product was purified by flash column chromatography (silica gel, 7 M on of NH3 in MeOH in DCM 0/100 to 50/50). The desired fractions were collected and the solvents evaporated in vacuo to yield a crude that was ved in HCl (6 mL, 36 mmol, 6 M in isopropyl alcohol) and the mixture was stirred at room temperature for 1 hour. The solvents evaporated in vacuo.

Then the residue was taken up in DCM and isopropyl alcohol and solid NaHC03 was added and the mixture was stirred at room temperature for 2 hours. The solids were filtered off and the filtrate was evaporated in vacuo to yield intermediate A32 (400 mg, 136% yield) as a sticky oil used in the next reaction step without further purification.

Example A3 3 Preparation of intermediate A33: 0 OMe — R Br F H2N To a mixture of intermediate A12 (7.5 g, 18.281 mmol) and methyl 4-fluoro-1H-pyrrole- 2-carboxylate (2.9 g, 20.263 mmol) in MeCN (150 mL) was added DBU (5.5 mL, 36.814 mmol) at room temperature. The mixture was stirred at 90 °C for 16 hours. After cooling, the solvent was mostly evaporated and the residue dissolved in DCM and washed with 0.5 M HCl. The organic layer was separated, dried (Na2S04), filtered and concentrated in vacuo. The residue was dissolved in DCM (100 mL) and TFA (15 mL) was added. The mixture was stirred at room temperature for 2 hours. The solvents were evaporated in vacuo. The mixture was d with sat. Na2C03 and ted with DCM. The organic layer was separated, dried (Na2S04), d and the solvent ated in vacuo. The crude product was purified by flash column chromatography (silica gel, MeOH in DCM 0/100 to 1/99). The d fractions were collected and trated in vacuo to yield intermediate A33 (4.78 g, 70% yield) as an off-white solid. e A34 Preparation of intermediate A34: _R Br O F The intermediate 34 was prepared from intermediate A33 accordingly to the synthetic procedure described in example A15. Flash column chromatography (silica gel, MeOH in DCM, 0/100 to 1/99) to yield intermediate A34 as an off-white solid (4.3 g, 98% yield).

Example A3 5 Preparation of ediate A35: S N Br Phosphoruspentasulfide (14 g, 63.021 mmol) was added to a solution of intermediate A34 (4.3 g, 12.604 mmol) in THF (150 mL) and the mixture was heated at 70 °C for 24 hours.

The on was filtered through celite and washed with THF. The filtrate was concentrated in vacuo. The residue was purified by flash column chromatography (silica gel; DCM). The desired fractions were ted and concentrated in vacuo to yield intermediate A35 (3.65 g, 81% yield) as a pale yellow solid.

Example A36 Preparation of intermediate A36: F Br tert—Butylhydroperoxide (70%, 5.406 mL, 38 mmol) was added to a solution of intermediate 35 (1.350 g, 3.779 mmol) in 7 N NH3 in MeOH (40 mL). The mixture was stirred at room temperature for 40 hours. The solvent was partially evaporated in vacuo and the residue d with DCM and washed with a diluted Na2C03 solution. The organic layer was separated, dried (NaZSO4), filtered and the solvents evaporated in vacuo. The crude product was purified by flash column chromatography (silica gel, 7 M solution of NH3 in MeOH in DCM 0/100 to 2/98). The desired fractions were collected and concentrated in vacuo to afford intermediate A36 (990 mg, 77% yield) as a yellow solid. 2012/053863 Example A37 Preparation of intermediate A37: F N Toluene (20 mL) was added to a mixture of ediate A36 (400 mg, 1.176 mmol), a)3 (0.108 g, 0.118 mmol), BINAP (0.22 g, 0.353 mmol) and sodium tert—butoxide (0.203 g, 2.177 mmol) under nitrogen at room temperature. The e was flushed with nitrogen for a few min, then benzophenone imine (0.359 mL, 2.352 mmol) was added and the mixture was stirred at 90 °C for 16 hours. After cooling, the mixture was diluted with H20 and ted with DCM. The organic layer was separated, dried (Na2S04), filtered and the solvents concentrated in vacuo. The crude product was purified by flash column chromatography (silica gel, 7 N NH3 in MeOH in DCM 0/100 to 1/99 to 5/95). The desired fractions were collected and concentrated in vacuo to yield intermediate A37 (440 mg, 85% yield) as a yellow foam.

Example A3 8 Preparation of intermediate A38: F NH2 HCl (37% in H20, 500 uL, 16.182 mmol) was added to a solution of intermediate A37 (920 mg, 2.089 mmol) in isopropanol (20 mL). The mixture was stirred at room temperature for 20 min, then concentrated in vacuo and re-dissolved in 25 mL of isopropanol. Then NaHC03 was added and the mixture was stirred for 1 hour at room temperature. The mixture was filtered and the filtrate was concentrated in vacuo. The product was purified by flash column chromatography (silica gel, 7 N NH3 in MeOH in DCM 1/99 to 10/90). The desired fractions were collected and concentrated in vacuo to yield ediate A38 (470mg, 81% yield) as an off-white foam.

Example A39 Preparation of intermediate A39: O 6 o 0% Oxalyl de (5.175 mL, 61.16 mmol) was added dropwise to a solution ofDMSO (4.668 mL, 65.2 mmol) in DCM (103 mL) at -78 °C under nitrogen atmosphere. The mixture was stirred for 15 min at -78 °C. Then transhydroxy-l-proline methyl ester (10 g, 40.77 mmol) was added and the resulting mixture was stirred for 2 hours at -40 °C. Then Et3N (17 mL, 122 mmol) was added and the mixture was allowed to warm up slowly to room temperature and d overnight. Then the mixture was diluted with 10% citric acid solution and extracted with DCM. The organic layer was dried (Na2S04), filtered and concentrated in vacuo to yield intermediate A39 (10 g) as a brown oil.

The crude was used in the next step without further purification Example A40 Preparation of intermediate A40: 0 / 8 N4 F 0% oromethyl)trimethylsilane (8.768 g, 61.663 mmol) was added to a solution of intermediate A39 (10 g) in THF (114 mL) at 0 °C, followed by the addition of TBAF (1 M in THF, 2.47 mL, 247 mmol). The reaction e was left to warm up at room temperature and stirred for 18 hours. The mixture was quenched with sat. aq. NH4Cl. The 2O mixture was stirred for 15 min, then TBAF (1 M in THF, 5 mL, 5 mmol) was added and the mixture was d for 30 min The organic layer was separated and the aq. layer was extracted with EtZO. The combined organic phases were washed with H20 and brine solution, then dried over , filtered and concentrated in vacuo.

The crude product was purified by flash column chromatography (silica gel; heptane in AcOEt 0/100 to 90/10). The desired fractions were collected and concentrated in vacuo to yield intermediate A40 (7.8 g, 61% yield).

Example A41 ation of intermediate A41: FISN_< Thionyl chloride (14.352 mL, 196.633 mmol) was added to intermediate A40 (7.7 g, 24.579 mmol) in pyridine (188 mL). The mixture was stirred at 80 °C under nitrogen atmosphere for 1 hour. The mixture was quenched with H20, then extracted with EtZO. The organic layer was washed with HCl 1 M, NaHC03 sat. solution, dried over , filtered and concentrated in vacuo. The crude t was purified by flash column chromatography (silica gel; heptane in AcOEt 0/100 to 80/20). The desired fractions were collected and concentrated in vacuo to yield intermediate A41 (4.6 g, 63% yield) as a yellow oil.

Example A42 Preparation of intermediate A42: F\NH DDQ (16.607 g, 73.16 mmol) was added to intermediate A41 (7.2 g, 24.385 mmol) in dioxane (45 mL). The mixture was stirred at 85 °C for 104 hours. The mixture was filtered off and the filtrate was concentrated in vacuo. The residue was purified by flash column chromatography (silica gel; DCM in heptane 40/60). The desired fractions were collected and trated in vacuo to yield ediate A42 (4 g, 85% yield) as a brownish paste.

Example A43 Preparation of intermediate A43: 0 \R1 3 CY F DBU (2.85 mL, 19 mmol) was added to a mixture of intermediate A12 (6.07 g, 14.84 mmol) and intermediate A42 (2 g, 10.356 mmol) in MeCN (40 mL). Then the mixture was heated at 90 °C for 18 hours. The reaction was diluted with DCM and washed with HCl 1 N solution The organic layer was separated, dried (Na2S04), d and the solvent evaporated in vacuo. The t was d by flash column chromatography (silica gel; DCM). The desired fractions were collected and concentrated in vacuo to yield intermediate A43 as a sticky solid (4.6 g, 59% yield).

Example A44 Preparation of intermediate A44: ? Br The intermediate A44 was prepared from intermediate A43 according to the synthetic procedures described in examples A20-A23. The compound was used as a crude for the subsequent on and the yield assumed to be quantitative.

Example A45 Preparation of intermediate A45: 2012/053863 The reaction was set up in three batches. The total amount ofmaterial is reported NH3 (2 M in EtOH, 47 mL, 94 mmol) was added to ediate A44 (2.3 g, 5.46 mmol) and NH4Cl (2.315 g, 43.7 mmol). The mixture was heated under microwave irradiation at 170 °C for 45 min, then concentrated in vacuo. Another 45 mL of NH3 (2 M in EtOH) were added and the mixture was heated under microwave irradiation at 170 °C for 45 min. The mixture was filtered and concentrated in vacuo. The crude was purified by flash column chromatography (silica gel; MeOH in DCM 0/100 to 3/97). The desired fractions were collected and concentrated in vacuo to yield ediate A45 (2.1 g, 99% .

The intermediate A46 was prepared according to the synthetic procedures described in examples A3 7-A3 8: Example A46 Preparation of intermediate A46: Prepared from intermediate A45. Compound precipitated from the crude reaction mixture using DCM (89% yield).

The intermediate A47 was prepared according to the synthetic procedure described in examples A9-Al 1: Example A47 Preparation of intermediate A47: +0 Br Prepared from carbamic acid, N—[l-(5-bromofluorophenyl)-2,2-difluoro (hydroxymethyl)ethyl]—, 1,1-dimethylethyl ester. The crude product was triturated with e and filtered. The grey solid was dissolved in DCM and purified by column chromatography (silica gel; DCM). The desired fractions were collected and trated in vacuo to yield intermediate A47 (78% yield) as a white solid. _ 43 _ Example A48 Preparation of intermediate A48: CHF2 i0 Br NaH (60% sion in mineral oil, 269 mg, 6.723 mmol) was added to a mixture of methyl 2-pyrrolecarboxylate (841 mg, 6.723 mmol) in DMF (20 mL) at 0 °C under nitrogen. Then the mixture was stirred for 10 min at 0 °C and then a solution of intermediate A47 (2 g, 4.482 mmol) in DMF (10 mL) was added and the mixture was stirred at room temperature for 20 hours. The reaction was quenched with NH4Cl sat. and extracted with AcOEt. The organic layer was separated, dried (MgSO4), filtered and the solvent ated in vacuo to yield intermediate A48 (2.2 g, 100% yield) as an oil, which was used in next step without further ation.

The intermediate A49 was prepared according to the synthetic procedure described in example A20: Example A49 ation of intermediate A49: CHF2 ed from intermediate A48. Flash column chromatography (silica gel, AcOEt in heptane 0/100 to 15/85). to yield intermediate A49 (100% yield).

Example A50 Preparation of intermediate A50: _ 44 _ CHF2 N F Trimethylaluminum (2 M in toluene; 4.47 mL, 8.9 mmol) was added to a d mixture of intermediate A49 (1.75 g, 4.47 mmol) in THF (20 mL) at 0 °C in a sealed tube. The mixture was stirred at 100 °C for 2 hours. The mixture was cooled to room temperature, poured into a flask, cooled at 0 °C and quenched with sodium sulfate decahydrate. The mixture was stirred for 15 min, then filtered and the es were evaporated in vacuo to yield intermediate A49 (1.657 g, 103% yield) as a solid, which was used in next step without further purifications.

The intermediate A51 was ed according to the tic procedure described in example A16: Example A51 Preparation of intermediate A51: CHF2 N F Prepared from intermediate 50. Flash column chromatography (silica gel, MeOH in DCM 0/100 to 05/95) to yield intermediate A51 (52% yield) as a pale yellow solid.

Example A52 Preparation of intermediate A52: CHF2 N F NH3 aq. solution (7 mL) was added to a solution of intermediate A51 (700 mg, 1.866 mmol) in 7 N NH3 in MeOH (7 mL) and the mixture was heated at 90 °C in a sealed tube for 21 hours. Then the t was evaporated and more aq. NH3 and 7 N NH3 in MeOH were added. The mixture was stirred at 90 °C for 24 hours. The solvent was evaporated in vacuo. The crude product was purified by flash column chromatography (silica gel; MeOH in DCM 0/100 to 03/97). The desired fractions were collected and concentrated in vacuo to yield intermediate A52 (464 mg, 69% yield).

The intermediate A53 was ed according to the tic procedure described in examples A3 7-A3 8: Example A53 Preparation of intermediate A53: CHF2 N F Prepared from intermediate A52. Flash column chromatography (silica gel; 7 N NH3 in MeOH in DCM 0/100 to . The desired fractions were collected and concentrated in vacuo to yield ediate A53 (69% yield).

Example A54 Preparation of intermediate A54: 0 Br A drop of AcOH was added to a stirred solution of 2-amino(5-bromofluorophenyl)- 1,3-propanediol (4.2 g, 15.9 mmol) and triethyl orthopropionate (3.52 mL, 17.5 mmol) in DCE (80 mL) at room temperature. The mixture was heated at 80°C for 90 min, and then treated with aq. Na2C03 sat. and extracted with DCM. The organic layer was separated, dried (MgSO4), filtered and the solvent evaporated in vacuo to afford an oil (4.63 g), which was used in next step without further cation.

Example A55 Preparation of ediate A55: 0 Br NaH (60% dispersion in mineral oil, 735 mg, 18.4 mmol) was added to a solution of intermediate A54 (4.63 g, 15.3 mmol) in DMF (40 mL) at 0 °C under nitrogen. The e was stirred for 10 min at 0°C, then methyl iodide (1.91 mL, 30.65 mmol) was added. The mixture was stirred at room temperature for 90 min, then quenched with aq. sat.

NH4Cl and extracted with heptane. The organic layer was separated, dried (MgSO4), filtered and the solvent evaporated in vacuo to yield ediate A55 as an oil (4.73 g), which was used in next step without further purification.

Example A56 Preparation of intermediate A56: HO Br A solution of ediate A55 (4.95 g, 15.7 mmol) in HCl (6 M in H20, 40 mL) was heated at 100 °C for 1 hour. The solvent was then evaporated to give intermediate A56 as an oil (4.3 g), which was used in next step t further purification.

The intermediate A57 was prepared ing to the synthetic procedures described in examples A9-A11, A43, A20, A50, A35, A36: Example A57 Preparation of intermediate A57: Prepared from intermediate A56. Flash column chromatography (silica gel; 7 N NH3 in MeOH in DCM 0/100 to 5/95) to yield intermediate A57 (68% yield).

Example A58 Preparation of intermediate A58: W0 2012/120023 Copper iodide (84 mg, 0.41 mmol) was added to a suspension of intermediate A57 (617 mg, 1.47 mmol), sodium azide (242 mg, 3.67 mmol), N,N ’-dimethylethylendiamine (142 uL, 1.32 mmol) and Na2C03 (447 mg, 4.41 mmol) in DMSO (13 mL) and the reaction was degassed. The mixture was heated at 110 0C for 25 hours, then quenched with 1 M HCl and the water layer basified with NH4OH and extracted with AcOEt (3x). The combined organic layers were dried (MgSO4), filtered and concentrated. The crude product was purified by flash column chromatography (silica, 7 N solution of NH3 in MeOH in DCM 0/100 to 5/95). The desired fractions were collected and concentrated in vacuo to yield intermediate A58 (480 mg, 92% yield).

Preparation of the final compounds Example B1 Preparation of compound 1: methyl(3 idinyl-phenyl)-3,4-dihydropyrrolo [1,2-a]pyrazinylamine / N \Il _ \ N . trifluoroacetate salt 3)4 (57 mg, 0.049 mmol) was added to a stirred suspension of intermediate A18 (300 mg, 0.99 mmol), pyrimidineboronic acid (367 mg, 2.96 mmol) and K2C03 (409 mg, 2.96 mmol) in a mixture of 1,4-dioxane (4 mL) and EtOH (0.4 mL) in a sealed tube.

The mixture was heated at 150 °C for 30 min under microwave irradiation. After cooling to room temperature, the mixture was diluted with H20 and extracted with DCM. The c layer was separated, dried (MgSO4), filtered and the solvents were evaporated in vacuo.

The crude product was purified by short column chromatography (silica gel; 7 M solution ofNH3 in MeOH/DCM 0/100 to 3/97). The desired fractions were collected and concentrated in vacuo to give a solid that was ated with EtZO, sonicated, filtered and dried in vacuo at 50 °C to yield a solid that was further purified by reverse phase HPLC (Gradient from 80% of a 0.1% TFA on in H20, 20% MeCN to 0% of a 0.1% TFA solution in H20, 100% MeCN) to yield compound 1 (90.3 mg, 22% yield) as a solid. 1H NMR (400 MHz, DMSO-d6) 8 ppm 1.74 (s, 3 H), 4.40 (d, J=13.6 Hz, 1 H), 5.03 (d, J=13.4 Hz, 1 H), 6.26 (dd, J=4.2, 2.5 Hz, 1 H), 7.19 (dd, J=4.2, 1.4 Hz, 1 H), 7.31 (t, J=1.6 Hz, 1 H), 7.45 (br. d, J=8.1 Hz, 1 H), 7.54 (t, J=7.9 Hz, 1 H), 7.75 (br. d, J=7.9 Hz, 1 H), 7.91 (br. s, 1 H), 8.38 (br. s., 1 H), 9.16 (s, 2 H), 9.21 (br. s, 1 H), 9.22 (s, 1 H), 10.23 (br. s, 1 W0 2012/120023 2012/053863 e B2 Preparation of compound 2: rac(3',5'-dichloro-biphenylyl)methyl-3,4-dihydropyrrolo [1,2-a]pyrazinylamine Pd(PPh3)4 (30.4 mg, 0.026 mmol) was added to a stirred sion of intermediate A18 (160 mg, 0.526 mmol), 2,3-dichlorophenyl-boronic acid (120.4 mg, 0.631 mmol) and K2C03 (218 mg, 1.58 mmol) in a e of 1,4-dioxane (4 mL) and EtOH (0.4 mL) in a sealed tube. The mixture was heated at 60 °C for 18 hours. After cooling to room temperature, the mixture was diluted with H20 and NH4Cl (aq. sat. solution) and extracted with DCM. The organic layer was separated, dried (Na2S04), filtered and the solvents were evaporated in vacuo. The crude product was purified by short column chromatography (MeOH in DCM 0/100 to 3/97). The desired fractions were collected and concentrated in vacuo to give a solid that was triturated with DIPE, filtered and dried in vacuo at 50 °C to yield compound 2 (136 mg, 70% yield) as a solid. 1H NMR (500 MHz, CDC13) 8 ppm 1.56 (s, 3 H), 4.11 (br. s, 2 H), 4.05 (d, J=12.4 Hz, 1 H), 4.10 (d, J=12.7 Hz, 1 H), 6.18 (dd, J=3.8, 2.6 Hz, 1 H), 6.43 (dd, J=3.8, 1.4 Hz, 1 H), 6.75 (dd, J=2.3, 1.4 Hz, 1 H), 7.32 (t, J=1.7 Hz, 1 H), 7.36 — 7.42 (m, 2 H), 7.43 (d, J=1.7 Hz, 2 H), 7.53 (dt, J=6.9, 1.9 Hz, 1 H), 7.65 - 7.71 (m, 1 H).

Example B3 2O Preparation of nd 3: racchloro-pyridinecarboxylic acid[3-(1-amino methyl-3 ,4-dihydro-pyrrolo[1,2-a]pyrazin-3 -yl)-phenyl]-amide NH4Cl (94 mg, 1.75 mmol) was added to a suspension of intermediate A26 (180 mg, 0.44 mmol) in a 2 M on of NH3 in EtOH (8.23 mL) and the mixture was heated at 80 °C for 6 days. The solvent was evaporated in vacuo and the residue suspended in DCM and washed with H20. The organic layer was separated, dried (MgSO4), filtered and the solvents evaporated in vacuo. The product was purified by flash column chromatography (silica gel, 7 M solution of NH3 in MeOH/DCM 0/100 to 10/90). The desired fractions were collected and the solvents evaporated in vacuo to yield compound 3 (28 mg, 17% yield) as a white solid. 1H NMR (500 MHz, CDC13) 8 ppm 1.56 (s, 3 H), 2.96 (br. s., 2 H), 4.06 (d, J=12.7 Hz, 1 H), 4.14 (d, J=13.3 Hz, 1 H), 6.17 (dd, J=3.8, 2.6 Hz, 1 H), 6.46 (dd, J=3.8, 1.2 Hz, 1 H), 6.75 (dd, J=2.3, 1.4 Hz, 1 H), 7.30 (br. d, J=7.8 Hz, 1 H), 7.35 (t, J=8.1 Hz, 1 H), 7.68 — 7.73 (m, 1 H), 7.88 (dd, J=8.4, 2.3 Hz, 1 H), 7.91 (t, J=1.7 Hz, 1 H), 8.25 (d, J=8.4 Hz, 1 H), 8.57 (d, J=2.0 Hz, 1 H), 9.86 (br. s., 1 H).

Example B4 Preparation of compound 4: racmethoxy-pyrazinecarboxylic acid [3-(1-amino methyl-3 ,4-dihydro-pyrrolo[ l ,2--a]pyrazinyl)--phenyl] -amide l/E:jo -Methoxy-pyrazinecarboxylic acid (56.4 mg, 0.36 mmol) was added to a solution of 4-(4,6-dimethoxy-l,3,5-triazinyl)methylmorpholinium chloride (1 11 mg, 0.4 mmol) in MeOH (4 mL). The mixture was stirred at room temperature for min. Then the mixture was cooled to 0 °C and a solution of intermediate A25 (80 mg, 0.33 mmol) in MeOH (2 mL) was added. The mixture was warmed to room temperature and stirred for 3 hours. The mixture was treated with a sat. solution of Na2C03 and H20 and extracted with DCM. The organic layer was separated, dried (NaZSO4), filtered and the solvents evaporated in vacuo. The crude product was triturated with EtZO and then was purified by flash column tography (silica gel; AcOEt in heptane 50/50). The desired fractions were collected and the solvents evaporated in vacuo to yield compound 4 (65 mg, 52% yield) as a white solid. 1H NMR (500 MHz, G) 8 ppm 1.36 (s, 3 H), 4.03 (s, 3 H), 3.99 — 4.11 (m, 2 H), 6.06 (br. s., 2 H), 6.02 (dd, J=3.5, 2.6 Hz, 1 H), 6.52 (dd, J=3.5, 1.2 Hz, 1 H), 6.87 (t, J=1.7 Hz, 1 H), 7.26 (t, J=7.8 Hz, 1 H), 7.28 — 7.33 (m, 1 H), 7.72 (dt, J=7.5, 1.7 Hz, 1 H), 8.02 (br. s, 1 H), 8.43 (d, J=1.2 Hz, 1 H), 8.90 (d, J=1.2 Hz, 1 H), 10.33 (br. s., 1 H).

Example B5 Preparation of compound 5: (R)chloro-pyridinecarboxylic acid amino methyl-3 ,4-dihydro-pyrrolo[ l yrazin-3 -yl)fluoro-phenyl] -amide ZI / -Chloro-pyridinecarboxylic acid (122 mg, 0.774 mmol) was added to a on of 4- (4,6-dimethoxy-l,3,5-triazinyl)methylmorpholinium chloride (214 mg, W0 2012/120023 0.774 mmol) in MeOH (4 mL). The mixture was stirred at room temperature for min.. Then the mixture was cooled to 0 °C and a solution of intermediate A32 (200 mg, 0.774 mmol) in MeOH (3 mL) was added. The mixture was warmed to room temperature and stirred for 90 min. The mixture was concentrated in vacuo in a cold bath, and then it was treated with a sat. on of Na2C03 and H20 and extracted with DCM. The organic layer was separated, dried (MgSO4), filtered and the solvents evaporated in vacuo. The crude product was purified by flash column chromatography (silica gel, 7 N NH3 in MeOH in DCM 0/100 to 2/98). The desired fractions were collected and the solvents evaporated in vacuo to yield a residue that was triturated with EtZO to yield compound 5 (65 mg, 21% yield) as a white solid. 1H NMR (500 MHz, CDCl3) 8 ppm 1.56 (s, 3 H), 4.20 (br. d, J=12.7 Hz, 1 H), 4.28 (br. d, J=12.4 Hz, 1 H), 4.59 (br. s., 2 H), 6.16 (dd, J=3.5, 2.6 Hz, 1 H), 6.43 (br. d, J=2.6 HZ, 1 H), 6.74 - 6.78 (m, 1 H), 7.06 (dd, J=11.7, 8.8 HZ, 1 H), 7.79 (dd, J=6.9, 2.6 Hz, 1 H), 7.87 (dd, J=8.4, 2.3 Hz, 1 H), 8.02 (ddd, J=9.0, 4.0, 3.2 Hz, 1 H), 8.23 (d, J=8.4 Hz, 1 H), 8.56 (d, J=2.0 Hz, 1 H), 9.82 (br. s., 1 H).

Example B6 Preparation of nd 6: (R)Cyano-pyridinecarboxylic acid [3-(1-amino methyl-3 ydro-pyrrolo[1,2-a]pyrazin-3 -yl)fluoro-phenyl]-amide ZI / -Cyano-pyridinecarboxylic acid (115 mg, 0.774 mmol) was added to a solution of 4- 2O (4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (214 mg, 0.774 mmol) in MeOH. The mixture was stirred at room temperature for min. Then, the mixture was cooled to 0 °C and a solution of intermediate A32 (200 mg, 0.774 mmol) in MeOH was added (total amount ofMeOH 4mL). The e was warmed to room temperature and stirred for 3 hours. The mixture was concentrated in vacuo in a cold bath, and then it was d with a sat. solution of Na2C03 and H20 and ted with DCM. The c layer was ted, dried (MgSO4), filtered and the solvents evaporated in vacuo. The crude product was purified by flash column chromatography (silica gel, 7 N NH3 in MeOH in DCM 0/100 to 2/98). The desired fractions were collected and the solvents evaporated in vacuo to yield a residue that was triturated with EtZO to yield compound 7 (110 mg, 37% yield) as a white solid. 1H NMR (500 MHz, CDCl3) 8 ppm 1.57 (s, 3 H), 4.21 (br. d, J=12.1 Hz, 1 H), 4.28 (br. d, J=12.7 Hz, 1 H), 4.37 (br. s., 1 H), 6.16 (dd, J=3.8, 2.6 Hz, 1 H), 6.43 (dd, J=3.8, 1.2 Hz, 1 H), 6.77 (dd, J=2.5, 1.3 Hz, 1 H), 7.08 (dd, J=11.7, 8.8 Hz, 1 H), 7.83 (dd, J=6.9, 2.9 Hz, 1 H), 8.01 (ddd, J=8.7, 4.0, 2.9 Hz, 1 H), 8.18 (dd, J=8.1, 2.0 Hz, 1 H), 8.40 (dd, J=8.1, 0.6 Hz, 1 H), 8.85 (br. d, J=1.2 Hz, 1 H), 9.85 (br. s., 1 H).

Example B7 ation of compound 7: Fluoro-pyridinecarboxylic acid [3-(1-amino fluoro-3 -methyl-3 ,4-dihydro-pyrrolo[1,2-a]pyrazin-3 -yl)fluoro-phenyl]-amide F/N / ZI / -Fluoro-pyridinecarboxylic acid (123 mg, 0.869 mmol) was added to a solution of 4- (4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (240 mg, 0.869 mmol) in MeOH (4 mL). The mixture was stirred at room temperature for 5 min. Then, the mixture was cooled to 0 °C and a on of intermediate A38 (200 mg, 0.724 mmol) in MeOH (2 mL) was added. The mixture was warmed to room temperature and d for 2 hours. The mixture was treated with a sat. solution of Na2C03 and H20 and extracted with DCM. The organic layer was separated, dried (Na2S04), filtered and the solvents evaporated in vacuo. The crude product was purified by flash column chromatography (silica gel; 7 N NH3 in MeOH in DCM 0/100 to 4/96). The desired fractions were collected and the ts evaporated in vacuo to yield a residue that was triturated with heptane to yield compound 8 (196 mg, 68% yield) as a white solid. 1H NMR (400 MHz, DMso—dfi) 5 ppm 1.41 (s, 3 H), 3.98 (br. d, J=12.7 Hz, 1 H), 4.10 (br. d, J=12.5 Hz, 1 H), 6.16 (br. s., 2 H), 6.41 (d, J=1.6 Hz, 1 H), 6.94 (dd, J=3.4, 2.0 Hz, 1 H), 2O 7.16 (dd, J=12.0, 8.8 Hz, 1 H), 7.75 (ddd, J=8.8, 4.2, 2.8 Hz, 1 H), 7.97 (td, J=8.7, 2.8 Hz, 1 H), 8.11 (dd, J=7.5, 2.7 Hz, 1 H), 8.21 (dd, J=8.8, 4.6 Hz, 1 H), 8.73 (d, J=2.8 Hz, 1 H), .51 (br. s, 1 H).

Example B8 Preparation of compound 8: (R)methoxy-pyrazinecarboxylic acid [3-(1-amino 3 -methyl-3 ,4-dihydro-pyrrolo[1,2-a]pyrazin-3 -yl)fluoro-phenyl]-amide N OMe -Methoxy-pyrazinecarboxylic acid (134 mg, 0.869 mmol) was added to a solution of 4- (4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (240 mg, 0.869 mmol) in MeOH (4 mL). The mixture was stirred at room temperature for min. Then, the mixture was cooled to 0 °C and a solution of intermediate A38 (200 mg, 0.724 mmol) in MeOH (2 mL) was added. The mixture was warmed to room temperature and stirred for 2 hours. The mixture was treated with a sat. on of Na2C03 and H20 and extracted with DCM. The organic layer was separated, dried (Na2S04), filtered and the solvents evaporated in vacuo. The crude product was purified by flash column chromatography (silica gel, 7 N NH3 in MeOH in DCM 0/100 to 4/96). The desired ons were collected and the solvents evaporated in vacuo to yield a residue that was triturated with e to yield compound 8 (213 mg, 71% yield) as a white solid. 1H NMR (400 MHz, DMso—dfi) 5 ppm 1.41 (s, 3 H), 3.97 (br. d, J=12.9 Hz, 1 H), 4.02 (s, 3 H), 4.09 (br. d, J=12.5 Hz, 1 H), 6.12 (br. s., 2 H), 6.40 (d, J=1.8 Hz, 1 H), 6.93 (dd, J=3.2, 1.8 Hz, 1 H), 7.15 (dd, J=12.0, 8.8 Hz, 1 H), 7.72 (ddd, J=8.8, 4.2, 3.0 Hz, 1 H), 8.12 (dd, J=7.4, 2.8 Hz, 1 H), 8.41 (d, J=1.4 Hz, 1 H), 8.87 (d, J=1.2 Hz, 1 H), 10.40 (br. s, 1 H).

Example B9 Preparation of compound 9: (R)cyano-pyridinecarboxylic acid [3-(1-amino methyltrifluoromethyl-3 ,4-dihydro-pyrrolo[1,2-a]pyrazin-3 -yl)fluoro-phenyl]-amide F30 / / N ZI | .trifluoroacetate salt -Cyano-pyridinecarboxylic acid (82 mg, 0.551 mmol) was added to a solution of 4- (4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (168 mg, 0.606 mmol) in MeOH (3 mL). The mixture was stirred at room temperature for 2O 5 min. Then, the mixture was cooled to 0 °C and a solution of intermediate A46 (200 mg, 0.551 mmol) in MeOH (2 mL) was added. The mixture was warmed to room ature and stirred for 18 hours. The mixture was concentrated in vacuo in a cold bath, and then it was d with sat. Na2C03 solution and extracted with DCM. The organic layer was separated, dried (Na2S04), filtered and concentrated in vacuo.

The crude product was purified by flash column tography a gel, MeOH in DCM 0/100 to 4/96) The desired fractions were collected and the solvent evaporated in vacuo. The compound was triturated with EtZO to yield a mixture that was repurified by flash column chromatography (silica gel, MeOH in DCM 0/100 to 4/96) The desired fractions were collected and the t evaporated in vacuo to yield an impure fraction, that was purified by RP HPLC on (C18 e 30 x 100 5um). Mobile phase (Gradient from 80% of a 0.1% TFA solution in H20, 20% MeCN to 0% of a 0.1% TFA solution in H20, 100% MeCN) of compound 9 (121.3 mg, 39% yield) as a white solid. 1H , yielding NMR (500 MHz, DMso—dfi) 5 ppm 1.79 (s, 3 H), 4.50 (br. d, J=13.6 Hz, 1 H), 4.92 (br. d, J=13.3 Hz, 1 H), 7.31 (dd, J=11.8, 8.7 Hz, 1 H), 7.51 (br. s, 1 H), 7.86 — 7.93 (m, 2 H), 7.95 (br. s, 1 H), 8.25 (d, J=8.1 Hz, 1 H), 8.58 (dd, J=8.4, 2.0 Hz, 1 H), 8.87 (br. s., 1 H), 9.20 (d, J=1.2 Hz, 1 H), 9.55 (br. s., 1 H), 10.67 (br. s., 1 H), 10.99 (br. s, 1 H).

Example B10 Preparation of compound 10: (R)difluoromethyl-1H-pyrazole-3 -carboxylic acid [3 -(1- amino-3 -methyltrifluoromethyl-3 ,4-dihydro-pyrrolo[1,2-a]pyrazin-3 -yl)fluoro- phenyl]-amide oromethyl-1H-pyrazolecarboxylic acid (31 mg, 0.193 mmol) was added to a solution of 4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium chloride (59 mg, 0.212 mmol) in MeOH (3mL). The mixture was stirred for 5 min at room temperature. The mixture was cooled to 0 °C and intermediate A46 (70 mg, 0.193 mmol, previously treated with NH3 in MeOH to generate the free base) in MeOH (2mL) was added. Then the mixture was stirred at room temperature for 18 hours.

The mixture was concentrated in vacuo in a cold bath, and then it was treated with sat.

Na2C03 solution and extracted with DCM. The organic layer was separated, dried (NaZSO4), filtered and concentrated in vacuo. The crude product was purified by flash column chromatography (silica gel; MeOH in DCM 0/100 to 4/96) The d ons were collected and the t evaporated in vacuo. The compound was triturated with 2O EtZO, to yield compound 10 (56 mg, 62% yield) as a white solid. 1H NMR (500 MHz, DMso—dfi) 5 ppm 1.40 (s, 3 H), 4.13 (br. d, J=13.0 Hz, 1 H), 4.29 (br. d, J=12.7 Hz, 1 H), 6.25 (br. s., 2 H), 6.87 (br. s, 1 H), 7.01 (d, J=2.3 Hz, 1 H), 7.16 (dd, , 9.0 Hz, 1 H), 7.59 (br. s, 1 H), 7.63 — 7.69 (m, 1 H), 7.92 (t, J=58.7 Hz, 1 H), 8.05 — 8.10 (m, 1 H), 8.41 (d, J=2.3 Hz, 1 H), 10.34 (s, 1 H). e B1 1 Preparation of compound 11: methoxy-pyridinecarboxylic acid [3-(1-amino difluoromethyl-3 ,4-dihydro-pyrrolo[1,2-a]pyrazin-3 -yl)fluoro-phenyl] -amide, compound 12: (R*)methoxy-pyridinecarboxylic acid [3-(1-aminodifluoromethyl- 3,4-dihydro-pyrrolo[1,2-a]pyrazinyl)fluoro-phenyl]-amide and compound 13: (S*)methoxy-pyridinecarboxylic acid [3 -(1-amino-3 -difluoromethyl-3 ,4-dihydro- pyrrolo[1,2-a]pyrazin-3 -yl)fluoro-phenyl]-amide /N OMe CHF2 Elm/[jN \ N OMe N OMe / / 3DElm/E} CHF2 13gCHF2 * N \ *S Elm/[jN \ N N o 0 F F -Methoxy-pyrazinecarboxylic acid (130 mg, 0.841 mmol) was added to a mixture of 4-(4,6-dimethoxy-1,3,5-triazinyl)methylmorpholinium de (233 mg, 0.841 mmol) in MeOH (4mL). The mixture was stirred for 5 min at room temperature, then cooled to 0 °C and intermediate A53 (225 mg, 0.765 mmol) in MeOH (4mL) was added.

The mixture was stirred at room temperature for 16 hours, then treated with sat. Na2C03 and stirred for a few min. The solvent was concentrated, H20 was added and extracted with a e of DCM/MeOH (9:1). The organic layer was separated, dried ), filtered and concentrated in vacuo. The crude t was triturated with DCM and filtered to give a first batch of compound 11.The filtrates were evaporated and purified by flash column chromatography (silica gel, MeOH in DCM 0/100 to 7/93). The desired fractions were collected and the solvents evaporated in vacuo to yield a second batch of compound 11, that was combined with the previous one. The racemic nd was purified by chiral SFC on CHIRALCEL (OD-H 5pm, 250 x 20mm). Mobile phase (60% C02, 40% EtOH), yielding compound 12 (57 mg, 17% yield). 1H NMR (500 MHZ, DMSO-dG) 8 ppm 4.02 (s, 3 H) 4.28 (br. (1, J=13.0 HZ, 1 H) 4.61 (br. (1, J=13.0 HZ, 1 H) 6.01 (dd, J=3.3, 2.7 HZ, 1H) 6.16 (t, J=55.5 HZ, 1 H) 6.40 (br. s., 2 H) 6.53 (d, J=2.6 HZ, 1 H) 6.98 (br. s, 1 H) 7.11 - 7.19 (m, 1 H) 7.73 — 7.78 (m, 1 H) 8.11 (dd, J=7.1, 2.7 Hz, 1 H) 8.41 (d, J=1.2 Hz, 1H) 8.87 (d, J=1.2 Hz, 1 H) 10.42 (br. s, 1 H) and compound 13 (72 mg, 21% yield), for which the 1H NMR spectrum was in agreement with the one of compound 12.

Table 1 .M.-Method RNo. Am:I Il-aanchmNON RS CFC30OH 3 B 1 1 0che.mStMSalt R / CF3COOH R / CF3COOH R / CF3COOH 1 1 F _ 57 _ Co. No. 1, 9, 15 and 20 were obtained as a trifluoroacetate salt (.CF3COOH).

C. Analytical Part LCMS For (LC)MS-characterization of the compounds of the present invention, the ing methods were used.

General procedure A The UPLC (Ultra Performance Liquid Chromatography) measurement was performed using an Acquity UPLC (Waters) system comprising a sampler organizer, a binary pump with degasser, a four column’s oven, a array detector (DAD) and a column as specified in the respective methods. The MS detector was configured with an ospray ionization source. Mass spectra were acquired on a single quadrupole SQD detector (Waters) by scanning from 100 to 1000 in 0.1 second using an inter- channel delay of 0.08 seconds. The capillary needle voltage was 3.0 kV. The cone voltage was 25 V for positive ionization mode and 30 V for negative tion mode.

The source temperature was maintained at 140 oC. Nitrogen was used as the nebulizer gas. Data acquisition was performed with MassLynX-Openlynx software.

Method 1: In addition to the general procedure A: Reversed phase UPLC was carried out on a RRHD Eclipse Plus-C18 (1.8 um, 2.1 X 50 mm) from Agilent, with a flow rate of 1.0 ml/min, at 50 °C without split to the MS detector. The nt conditions used are: 95 % A (6.5 mM NH4AcO in leCN 95/5), 5 % B (MeCN), to 40 % A, 60 % B in 3.8 min, to 5 % A, 95 % B in 4.6 min, kept till 5.0 min. Injection volume 2 uL.

General grocedure B The HPLC measurement was performed using an HP 1100 (Agilent Technologies) system comprising a pump (quaternary or binary) with degasser, an autosampler, a column oven, a diode-array detector (DAD) and a column as specified in the tive methods. The MS detector (SQD, TOF) was configured with an electrospray tion source. Nitrogen was used as the nebulizer gas. The source temperature was maintained at 140 oC. Data acquisition was performed with MassLynX-OpenlynX software.

B1: Mass spectra were acquired on a single quadrupole SQD detector by scanning from 100 to 1000 in 0.1 second using an inter-channel delay of 0.08 second. The capillary needle voltage was 3.0 kV. The cone voltage was 20 V for positive tion mode and 30 V for negative ionization mode.

B2: Mass spectra were ed on a Time of Flight (TOF) detector by scanning from 100 to 750 in 0.5 seconds using a dwell time of 0.3 seconds. The capillary needle voltage was 2.5 kV for positive ionization mode and 2.9 kV for negative ionization mode. The cone voltage was 20 V for both positive and negative ionization modes.

Leucine-Enkephaline was the standard substance used for the lock mass ation.

Method 2.‘ In addition to the general ure B1: Reversed phase HPLC was carried out on an Eclipse Plus-C18 column (3.5 um, 2.1 X 30 mm) from Agilent, with a flow rate of 1.0 mL/min, at 60 °C. The gradient conditions used are: 95 % A (6.5 mM NH4AcO in HzO/MeCN 95/5), 5 % B (MeCN/ MeOH 1/1), to 100 % B in 5.0 min, kept to 5.15 min and equilibrated to l ions at 5.30 min until 7.0 min. Injection volume 2 uL.

Method 3: In addition to the general procedure B2: Reversed phase HPLC was d out on a Eclipse Plus-C18 column (3.5 um, 2.1 X 30 mm) from Agilent, with a flow rate of 1.0 mL/min, at 60°C. The nt conditions used are: 95 % A (6.5 mM NH4AcO in HzO/MeCN 95/5), 5 % B (MeCN/MeOH, 1/1) to 100 % B in 5.0 min, kept till 5.15 min and equilibrated to initial conditions at 5.3 min until 7.0 min. Injection volume 2 uL.

Method 4: In addition to the general procedure B2: Reversed phase HPLC was carried out on a Eclipse Plus-C18 column (3.5 um, 2.1 X 30 mm) from Agilent, with a flow rate of 1.0 ml/min, at 60 °C. The gradient conditions used are: 95 % A (6.5 mM NH4AcO in HzO/MeCN 95/5), 5 % B (MeCN), kept 0.2 min, to 100 % B in 3.0 min, kept to 3.15 2012/053863 min and equilibrated to initial conditions at 3.3 min until 5.0 min. Injection volume 2 General procedure C.' The LC measurement was performed using a UPLC (Ultra Performance Liquid Chromatography) Acquity (Waters) system comprising a binary pump with degasser, an autosampler, a diode-array detector (DAD) and a column as ed in the respective s below, the column is hold at a temperature of 40°C. The MS detector was configured with an electrospray ionization source. Mass spectra were acquired on a triple quadrupole Quattro detector s) by scanning from 100 to 1000 in 0.2 seconds using an inter-scan delay of 0.1 seconds. The capillary needle voltage was 3 kV and the source temperature was maintained at 130 °C. Cone voltage was 20V for positive and negative ionization mode. en was used as the nebulizer gas. Data acquisition was performed with MassLynX-OpenlynX software (Waters).

Method 5.' In addition to the general procedureReversed phase UPLC was carried out on a Waters Acquity BEH (bridged ethylsiloxane/silica hybrid) Phenyl-Hexyl column (1.7 um, 2.1 X 100 mm) with a flow rate of 0.343 mL/min. Two mobile phases e phase A: 95 % 7 mM NH4AcO / 5 % MeCN, mobile phase B: 100 % MeCN) were employed to run a gradient condition from 84.2 % A and 15.8 % B (hold for 0.49 min) to 10.5 % A and 89.5 % B in 2.18 min, hold for 1.94 min and back to the initial conditions in 0.73 min, hold for 0.73 min. An injection volume of 2 ml was used.

Melting Points Values are either peak values or melt ranges, and are obtained with experimental uncertainties that are commonly associated with this analytical .

Mettler FP8 1HT/FP90 or FP62 apparatus For a number of compounds, g points were determined in open capillary tubes either on a Mettler FP62 or a r FP8 1HT/FP90 apparatus. Melting points were ed with a temperature gradient of 1, 3, 5 or 10°C/minute. Maximum temperature was 300 °C. The g point was read from a digital display.

For a number of compounds, melting points (m.p.) were determined with a WRS-2A melting point apparatus that was purchased from Shanghai Precision and Scientific Instrument Co. Ltd. Melting points were measured with a linear heating up rate of 0.2-5.0 oC/minute. The reported values are melt ranges. The m temperature was 300°C.

Table 2: Analytical data — Rt means retention time (in min), [M+H]+ means the protonated mass of the compound, method refers to the method used for . 1 0.83 87. 2 °C (FP81HT/FP90) 2 2.62 370 1 162.6 °C (FP81HT/FP90) 3 1.83 380 1 n.d. 4 1.57 377 1 221 °C (FP81HT/FP90) 2.81 398 3 197.3 °C (FP62) 6 2.27 389 4 180 °C (FP81HT/FP90) 7 1.68 400 1 197 °C (FP81HT/FP90) 8 1.64 413 1 211 °C (FP81HT/FP90) 9 2.09 457 1 150.2 °C (FP62) 2.23 471 1 204.1 °C (FP62) 11 2.51 431 5 252.7 °C (FP81HT/FP90) 12 2.50 431 5 n.d. 13 2.50 431 5 n.d. 14 1.97 418 1 224.9 °C (FP81HT/FP90) 1.98 475 1 242.4 °C (FP62) 16 1.38 386 1 n.d. 17 1.78 400 1 174 °C (FP81HT/FP90) 18 2.08 454 1 n.d. 19 2.91 450 2 >300 °C (FP62) 1.84 436 1 n.d. 21 1.81 436 1 n.d. 22 2.15 438 1 160.6 °C (FP62) 23 2.37 504 1 227 °C (FP62) 24 2.26 493 1 n.d. 2.28 480 1 n.d. 26 2.09 501 1 n.d.

W0 2012/120023 _ 61 _ 222 126.1 0C T/FP90) 28 2.21 493 1 121.8 0C (FP81HT/FP90) 29 2.21 480 1 134.7 0C (FP81HT/FP90) 2.22 480 1 137.6 0C (FP81HT/FP90) 31 2.52 501 5 253.5 0C (FP81HT/FP90) 32 2.54 501 5 250 0C (FP81HT/FP90) n.d. means not determined SFC-MS methods: General procedurefor SF-MS methods: The SFC measurement was performed using an Analytical SFC system from Berger ment comprises a FCM-l200 dual pump fluid control module for delivering carbon dioxide (CO2) and modifier, a CTC Analytics automatic liquid sampler, a TCM-2000O thermal control module for column heating from room temperature to 80°C. An Agilent 1100 UV photodiode array or equipped with a high-pressure flow cell standing up to 400 bars was used. Flow from the column was split to a MS ometer. The MS detector was configured with an atmospheric pressure ionization source. The following ionization ters for the Waters ZQ mass spectrophotometer are: corona: 9ua, source temp: 140 oC, cone: 30 V, probe temp 450 oC, extractor 3 V, desolvatation gas 4OOL/hr, cone gas 70 L/hr. Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Waters-Micromass MassLynX-Openlynx data system.

Method 1: In addition to the general procedure: The chiral separation in SFC was carried out on a CHIRALCEL OD-H DAICEL column (5 um, 4.6 X 250 mm) at 35 °C with a flow rate of 3.0 mL/min. The mobile phase is CO2, 40% EtOH (+ 0.3% iPrNH2) hold 7 min in isocratic mode.

Method 2.‘ In on to the general procedure: The chiral separation in SFC was carried out on a CHIRALPAK AD-H DAICEL column (10 um, 4.6 X 250 mm) at 35 °C with a flow rate of 3.0 . The mobile phase is CO2, 15 % EtOH, 15% isopropanol (+ 0.3% iPrNH2) hold 7 min in isocratic mode. _ 62 _ Table 3: Analytical SFC data — Rt means retention time (in min), [M+H]+ means the protonated mass of the compound, method refers to the method used for SFC/MS analysis of enantiomerically pure compounds.

Isomer Elution UV Area 0A) Method Order" 12 2.34 431 100 1 A 13 3.18 431 100 1 B 31 1.80 501 100 2 A 32 2.64 501 100 2 B *A means the first isomer that . B means the second isomer that elutes.

Optical Rotations: Optical rotations were measured on a Perkin-Elmer 341 polarimeter with a sodium lamp and reported as follows: [ochtoC (c g/100mL, solvent).

Table 4: ical data — Optical rotation values for enantiomerically pure compounds. nm w/V % 103.6 589 0.45 DVIF 20 6 91.4 589 0.47 DVIF 20 7 84.7 589 0.63 DVIF 20 8 104.0 589 0.53 DVIF 20 9 111.7 589 0.53 DVIF 20 12 198.0 589 0.26 DVIF 20 13 -207.5 589 0.86 DVIF 20 108.7 589 0.55 DVIF 20 16 -24.4 589 0.54 DVIF 20 17 -28.3 589 0.53 DVIF 20 18 -45.4 589 0.56 DVIF 20 27 -142 589 0.5 DVIF 20 _ 63 _ nm w/V % ° C 28 134.2 589 0.48 DMF 20 29 130.1 589 0.49 DMF 20 -110.7 589 0.5 EtOH 20 31 -109.8 589 0.48 DMF 20 32 107.9 589 0.47 DMF 20 Pharmacological examples The nds ed in the t invention are inhibitors of the B-site APP- cleaving enzyme 1 (BACEl). Inhibition of BACE1, an aspartic protease, is believed to be relevant for treatment of Alzheimer’s Disease (AD). The production and accumulation of B-amyloid peptides (AB) from the B-amyloid precursor protein (APP) is believed to play a key role in the onset and progression of AD. AB is produced from the amyloid sor protein (APP) by sequential cleavage at the N— and C-termini of the AB domain by B-secretase and y-secretase, respectively.

Compounds of Formula (I) are ed to have their effect substantially at BACE1 by virtue of their ability to t the enzymatic activity. The behaviour of such inhibitors tested using a biochemical Fluorescence Resonance Energy Transfer (FRET) based assay and a cellular odisa assay in SKNBE2 cells described below and which are suitable for the identification of such compounds, and more particularly the compounds according to Formula (I), are shown in Table 1.

Biochemical FRET based assay This assay is a Fluorescence Resonance Energy Transfer Assay (FRET) based assay. The substrate for this assay is an APP derived 13 amino acids peptide that contains the ‘Swedish’ Lys-Met/Asn-Leu mutation of the amyloid precursor protein (APP) etase cleavage site. This substrate also contains two fluorophores: (7-methoxy- coumarinyl) acetic acid (Mca) is a fluorescent donor with excitation wavelength at 320nm and on at 405nm and 2,4-Dinitrophenyl (an) is a proprietary quencher acceptor. The distance between those two groups has been selected so that upon light excitation, the donor fluorescence energy is significantly quenched by the acceptor, through resonance energy transfer. Upon ge by BACE1, the fluorophore Mca is separated from the quenching group an, restoring the full fluorescence yield of the donor.

The increase in fluorescence is linearly d to the rate of proteolysis (Koike H et al. J.

Biochem. 1999, 126, 23 5-242). _ 64 _ Briefly in a 384-well format recombinant BACEl protein in a final concentration of 1 ug/ml is incubated for 120 min at room temperature with 10 um substrate in incubation buffer (40mM Citrate buffer pH 5.0, 0.04% PEG, 4% DMSO) in the e or presence of compound. Next the amount of proteolysis is directly measured by fluorescence ement at T=0 and T=120 (excitation at 320nm and emission at 405nm). Results are expressed in RFU, as difference between T120 and TO A best-fit curve is fitted by a m sum of squares method to the plot of %Controlmin versus compound concentration. From this an IC50 value (inhibitory concentration causing 50% inhibition of activity) can be obtained.

LC = Median of the low control values = Low control: Reaction without enzyme HC = Median of the High control values = High Control: Reaction with enzyme %Effect = 100-[(sample-LC) / (HC-LC) *100] %Control = (sample /HC)*100 %Controlmin = (sample-LC) / (HC-LC) *100 The following exemplified compounds were tested ially as bed above and exhibited the following the activity: Table 5 Biochemical FRET based assay Co. No. pIC50 \DOOQQUI-BMNH 4.92 .43 6.87 6.63 7.43 7.71 7.38 7.48 7.47 y—x C 7.32 WO 20023 Biochemical FRET based assay Co. No. pIC50 11 6.97 12 7.43 13 4.74 14 6.76 7.44 16 7.31 17 7.17 18 7.08 19 6.75 6.99 21 7.02 22 6.65 23 6.74 24 5.50 5.30 26 5.54 27 <43 28 5.72 29 5.69 4.46 31 <43 32 5.76 Cellular alisa assay in SKNBE2 cells In two odisa assays the levels of ABtotal and A342 produced and secreted into the medium of human neuroblastoma SKNBE2 cells are quantified. The assay is based on the human neuroblastoma SKNBE2 expressing the wild type Amyloid Precursor Protein (hAPP695). The compounds are diluted and added to these cells, ted for 18 hours and then measurements of A1342 and A13tota1 are taken. A13tota1 and A1342 are measured by sandwich odisa. odisa is a sandwich assay using biotinylated antibody AbN/25 attached to streptaVidin coated beads and antibody Ab4G8 or cAb42/26 conjugated acceptor beads for the detection of A13tota1 and A1342 tively. In the presence of A13tota1 or A1342, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in light emission. Light emission is measured after 1 hour incubation (excitation at 650nm and on at 615nm).

A best-fit curve is fitted by a minimum sum of squares method to the plot of %Controlmin versus compound concentration. From this an IC50 value (inhibitory concentration causing 50% inhibition of activity) can be obtained.

LC = Median of the low control values = Low l: cells preincubated without compound, without biotinylated Ab in the odisa HC = Median of the High l values = High Control: cells preincubated without compound %Effect = 100-[(sample-LC) / (HC-LC) *100] %Control = (sample /HC)*100 %Controlmin = (sample-LC) / (HC-LC) *100 The following exemplified compounds were tested essentially as described above and ted the following the activity: Table 6 ar alisa assay in Cellular alisa assay in SKNBE2 cells SKNBE2 cells A342 Alitotal pIC50 pIC50 2 5.35 5.37 3 7 7.02 4 6.96 7.03 8.53 8.55 6 8.8 8.85 7 8.18 8.25 8 8.66 8.69 9 7.92 7.97 _ 67 _ Cellular alisa assay in Cellular alisa assay in SKNBE2 cells SKNBE2 cells Co. No.

A1342 Alitotal pIC50 pIC50 27 <5 <5 28 6.53 6.52 29 6.32 6.33 <5 <5 31 <5 <5 32 6.54 6.53 Demonstration ofin viva eflicacy AB peptide ng agents of the invention can be used to treat AD in mammals such as humans or alternatively demonstrating efficacy in animal models such as, but not limited to, the mouse, rat, or guinea pig. The mammal may not be diagnosed with AD, or may not have a genetic predisposition for AD, but may be transgenic such that it WO 20023 overproduces and eventually deposits AB in a manner similar to that seen in humans afflicted with AD.

AB peptide lowering agents can be administered in any standard form using any standard method. For example, but not limited to, AB peptide lowering agents can be in the form of liquid, tablets or capsules that are taken orally or by injection. AB peptide lowering agents can be administered at any dose that is sufficient to significantly reduce levels of AB peptides in the blood, blood plasma, serum, cerebrospinal fluid (CSF), or brain.

To ine whether acute administration of an AB42 peptide lowering agent would reduce AB peptide levels in vivo, non-transgenic s, e. g. mice or rats were used. Animals treated with the AB peptide lowering agent were ed and compared to those untreated or treated with e and brain levels of soluble AB42 and total AB were quantitated by standard techniques, for example, using ELISA. Treatment periods varied from hours (h) to days and were adjusted based on the results of the AB42 lowering once a time course of onset of effect could be established.

A typical protocol for measuring AB42 lowering in vivo is shown but it is only one of many variations that could be used to optimize the levels of detectable AB. For example, AB peptide lowering compounds were formulated in 20 % hydroxypropyl B cyclodextrin.

The AB peptide lowering agents were administered as a single oral dose (p.o.) or a single subcutaneous dose (s.c.) to ght fasted animals. After a certain time, usually 2 or 4 h (as indicated in Table 7), the animals were sacrificed and AB42 levels were ed.

Blood was collected by decapitation and exsanguinations in EDTA-treated collection tubes. Blood was centrifuged at 1900 g for 10 min (min) at 4 °C and the plasma recovered and flash frozen for later analysis. The brain was removed from the cranium and hindbrain. The cerebellum was removed and the left and right hemisphere were separated.

The left hemisphere was stored at -18 0C for quantitative analysis of test compound levels.

The right hemisphere was rinsed with ate-buffered saline (PBS) buffer and immediately frozen on dry ice and stored at -80 0C until homogenization for mical Mouse brains from non-transgenic animals were resuspended in 8 s of 0.4 % DEA (diethylamine) /50 mM NaCl containing protease tors (Roche-11873580001 or 04693159001) per gram oftissue, e.g. for 0.158 g brain, add 1.264 ml of 0.4 % DEA.

All samples were nized in the FastPrep-24 system (MP Biomedicals) using lysing matrix D (MPBio #6913-100) at 6m/s for 20 seconds. Homogenates were centrifuged at 221.300 x g for 50 min. The resulting high speed supematants were then transferred to fresh orf tubes. Nine parts of supernatant were neutralized with 1 part 0.5 M Tris- HCl pH 6.8 and used to quantify A13total and A1342.

To quantify the amount of A13total and A1342 in the soluble fraction of the brain homogenates, Enzyme-Linked-Immunosorbent-Assays were used . Briefly, the standards (a on of synthetic AB1-40 and , Bachem) were prepared in 1.5 ml Eppendorf tube in Ultraculture, with final concentrations ranging from 10000 to 0.3 pg/ml. The samples and rds were co-incubated with HRPO-labelled N—terminal antibody for A1342 detection and with the biotinylated main antibody 4G8 for A13total detection. 50 ul of conjugate/sample or conjugate/standards mixtures were then added to the antibody-coated plate (the capture antibodies selectively recognize the C—terminal end of A1342, antibody JRF/cA1342/26, for A1342 detection and the N—terminus of A13, dy JRF/rA13/2, for A13total detection). The plate was d to incubate overnight at 4 0C in order to allow formation of the antibody-amyloid complex. Following this incubation and subsequent wash steps the ELISA for A1342 quantification was finished by on of Quanta Blu fluorogenic peroxidase substrate ing to the manufacturer’s instructions (Pierce Corp, Rockford, II). A reading was performed after 10 to 15 min (excitation 320 nm /emission 420 nm).

For A13total detection, a Streptavidine-Peroxidase-Conjugate was added, followed 60 min later by an addional wash step and addition of Quanta Blu fluorogenic peroxidase 2O substrate according to the manufacturer’s instructions (Pierce Corp, rd, 11). A reading was performed after 10 to 15 min (excitation 320 nm /emission 420 nm).

In this model at least 20 % A1342 lowering compared to untreated animals would be advantageous.

The following exemplified compounds were tested essentially as described above and exhibited the following the activity: Table 7: Route of Time after (_%Ctrl)Mean (%Ctrl)_Mean administration administration p.o. means oral

Claims (12)

Claims

1. A compound of Formula (I) R2 R3 R1 N H2N N X4 L X1 X3 5 X2 or a tautomer or a stereoisomeric form thereof, wherein R1, R2, R3 are independently selected from the group consisting of hydrogen, halo, cyano, C1-3alkyl, mono- and polyhalo-C1-3alkyl, and C3-6cycloalkyl; R4 is selected from the group consisting of hydrogen, C1-3alkyl, methoxymethyl, C3-6cycloalkyl, mono- and polyhalo-C1-3alkyl, homoaryl, and heteroaryl; X1, X2, X3, X4 are independently C(R5) or N, provided that no more than two thereof 15 represent N; R5 is selected from the group ting of hydrogen, halo, cyano, C1-3alkyl, mono- and polyhalo-C1-3alkyl, and C3-6cycloalkyl; L is a bond or -NHCO-; 20 Ar is homoaryl or aryl; wherein homoaryl is phenyl or phenyl substituted with one, two or three substituents selected from the group consisting of halo, cyano, C 1-3alkyl, C1-3alkyloxy, mono- and polyhalo-C1-3alkyl, and mono- and polyhalo-C1-3alkyloxy; heteroaryl is ed from the group consisting of pyridyl, dyl, pyrazinyl, 25 pyridazyl, furanyl, thienyl, pyrrolyl, pyrazolyl, olyl, triazolyl, lyl, thiadiazolyl, oxazolyl, and oxadiazolyl, each optionally substituted with one, two or three substituents selected from the group consisting of halo, cyano, C1-3alkyl, C1-3alkyloxy, mono- and polyhalo-C1-3alkyl, and mono- and polyhalo-C1-3alkyloxy; or an addition salt or a solvate thereof.

2. The compound of claim 1 wherein, R1, R2and R3 are ndently selected from hydrogen and C1-3alkyl; 5 X1, X2, X3, X4 are independently C(R5) n each R5 is selected from hydrogen and halo; L is a bond or –NHCO-; 10 Ar is homoaryl or heteroaryl; n homoaryl is phenyl or phenyl substituted with one or two tuents selected from the group consisting of halo, cyano, C1-3alkyl, C1-3alkyloxy , and polyhalo-C1-3alkyloxy; heteroaryl is selected from the group consisting of pyridyl, pyrimidyl, and pyrazinyl, 15 each optionally substituted with one or two substituents selected from the group ting of halo, cyano, C1-3alkyl, C1-3alkyloxy, and polyhalo-C1-3alkyloxy; or an addition salt or a solvate thereof.

3. The compound of claim 1 wherein, R1, R2 and R3 are hydrogen; X1 is CF; 25 X2, X3, X4 are CH; L is a bond or -NHCO-; Ar is homoaryl or aryl; 30 wherein homoaryl is phenyl substituted with chloro; heteroaryl is selected from the group ting of pyridyl and pyrimidyl, each optionally substituted with one or two substituents selected from the group consisting of chloro, fluoro, cyano, methyl, and methoxy; or an addition salt or a solvate thereof.

4. The compound of claim 1 wherein the carbon atom substituted with R4 has the R-configuration.

5. The nd of claim 1 wherein R1 and R3 are hydrogen, R2 is hydrogen, fluoro, or trifluoromethyl; R4 is methyl or difluoromethyl; 5 X1 is CH or CF; X2, X3, and X4 are CH; L is -NHCO-; Ar is ropyridinyl, 5-cyanopyridinyl, 5-fluoropyridinyl, 5-cyano fluorooropyridinyl, oxypyrazinyl or 1-difluoromethylpyrazolyl; or an 10 addition salt or a solvate thereof.

6. A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in any one of claims 1 to 5 and a ceutically acceptable carrier.

7. A process for preparing a pharmaceutical composition as defined in claim 6, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as d in any one of claims 1 to 5.

8. A compound as defined in any one of claims 1 to 5 for use in the ent or prevention of Alzheimer's disease, mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.

9. The use of a compound as defined in any one of claims 1 to 5 or a pharmaceutical composition as defined in claim 6, in the manufacture of a medicament for treating a disorder selected from the group consisting of Alzheimer's disease, mild ive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, 30 dementia ated with stroke, dementia associated with Parkinson's disease and dementia associated with beta-amyloid.

10. A compound according to claim 1, substantially as herein described with nce to any one of the examples.

11. A pharmaceutical according to claim 6, ntially as herein described with reference to any one of the examples.

12. The use according to claim 9, ntially as herein described with reference to any one of the examples.